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ABSTRACT 
CML is a malignant disease that originates in the bone marrow stem cell, carrying the Philadelphia chromosome 
with the BCR-ABL fusion gene. This gene translates into an active tyrosine kinase, Bcr-Abl, affecting 
hematopoiesis, particularly resulting in increased numbers of white blood cells in the peripheral blood. Left 
untreated, CML progresses from a silent chronic phase (CP) to a life-threatening blastic phase (BP). After the 
millennium shift imatinib was introduced for the treatment of CML. Specifically targeting the Bcr-Abl 
oncoprotein, it was the first tyrosine kinase inhibitor (TKI) employed in cancer. It induced spectacular responses 
among CML-CP patients, strikingly reducing the risk of disease progression, combined with excellent 
tolerability. In this thesis we have studied various aspects of imatinib treatment in CML.  
   In a cohort of 45 newly diagnosed CML-CP patients initiated on imatinib, we consecutively assessed treatment 
responses by FISH, PCR and chromosome banding analysis (CBA). In a landmark analysis, an early favourable 
response, defined as less than 10% BCR-ABL-positive cells by FISH after 3 months of treatment, was identified 
as a predictive marker of an improved long-term clinical outcome. Among evaluable patients 51% achieved this 
response. A large majority, 95% of such responders, reached complete cytogenetic response within 12 months 
and 100% an event-free survival at 48 months.  
    We assessed the effect of imatinib treatment on neutrophil leukotriene (LT) signaling to evaluate its possible 
role as a clinical biomarker predictive of treatment response. Increased LT signaling has previously been 
suggested as a driver of leukocytosis in CML. The activity and expression of LTC4S, catalyzing formation of 
LTC4 from LTA4, were determined in neutrophils from 11 CML-CP patients during their initial phase of 
imatinib treatment, and the results related to the parallel development of BCR-ABL-expression. CD16+ 
neutrophils were isolated, their LTC4S activity measured and LTC4S expression determined at the protein and 
mRNA levels. In parallel, BCR-ABL expression was assessed by bone marrow CBA and by FISH on peripheral 
blood cells, including a combined May Grünewald Giemsa staining and FISH technique (MGG-FISH) to score 
neutrophilic cells. An aberrant expression of LTC4S in CML neutrophils was typically found, but it was rapidly 
normalized after initiation of imatinib treatment, later paralleled by a decreasing expression of BCR-ABL. The 
findings indicate that increased expression and activity of LTC4S in CML is a down-stream step of BCR-ABL 
activity, i.e. the Bcr-Abl protein directly or indirectly causes an upregulation of LTC4S. It is possible that an 
early evaluation of LTC4S expression during imatinib treatment could serve as a more rapid way of assessing 
treatment response than the current methods identifying BCR-ABL expression through CBA, FISH or qRT-
PCR.  
   We also defined real life outcome of patients with CML in Sweden during four decades and related the relative 
survival (RS) patterns to imatinib treatment and other management strategies. We assessed trends in survival and 
short-and long-term excess mortality among all patients (n=3,173) regardless of clinical trial enrollment. Patients 
were categorized into five age groups (<50, 50-59, 60-69, 70-79 and >79 years) and five calendar periods (1973-
1979, 1980-1986, 1987-1993, 1994-2000 and 2001-2008).  We found that throughout all calendar periods, age 
was a strong predictor of survival, with superior survival for the youngest patients. In analyses including age and 
period of diagnosis, RS improved with calendar period in all age groups, but most markedly in patients younger 
than 79 years of age, particulary those 70-79 years of age. Survival among all age groups was greatest in the last 
calendar period, mainly as a result of an increasing use of imatinib. However, elderly patients still do poorly. The 
Swedish CML registry data show that patients diagnosed 2002-2008, at the age of 70-79 years received TKI in 
66% and patients >80 years in  only 18% of the cases.  
   Finally, we compared the costs during the last decades with earlier decades treatment regimens and related the 
costs to the expected improved survival. Using Swedish real world national data from CML patients diagnosed 
in the country from 1973 to 2008 (n=1,778), we evaluated the incremental cost-effectiveness ratio (ICER) 
between three periods associated with broad implementation of imatinib (III), interferon-α and allogeneic stem 
cell transplantation (II), and symptomatic treatment (I), respectively. We observed substantial health gains over 
time, paralleled by increased treatment costs. The mean survival was 2.9, 9.2 and 18.5 years during periods I-III, 
respectively. The resulting ICER was £45 700 per QALY gained comparing periods III and II using a societal 
perspective. In a separate analysis by groups of age at diagnosis showed lower ICERs for individuals <50 years 
at diagnosis: £38 500 for the societal perspective. Since the prevalence of CML patients is increasing and 
assuming that 75% of each incident cohort was to receive imatinib at current prices, the imatinib budget would 
need to double by 2050. A future potential discontinuation of imatinib for selected excellent responders would 
reduce the ICER per QALY gained. Reduced drug cost of imatinib linked to the patent expiry of the drug will 
probably have a greater impact on ICER per QALY. An estimated price reduction of 80% (global competition) 
or 30% (expected change for biological drugs) would be associated with an ICER of £20 000 and £36 000, 
respectively, per QALY gained. 
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The term leukemia was coined by Virchow in 1845 as he recognized several cases of spleno-
megaly, anemia and massive granulocytosis and understood the neoplastic nature in patients 
with ”purulent” blood.1,2 The disease origin from the bone marrow was clarified by Neumann 
some years later.3 Nowell´s and Hungerford´s discovery of the Philadelphia chromosome in 
1960 was a breakthrough in cancer biology and CML. For the first time it was demonstrated 
that a chromosome change was associated with a specific type of leukemia.4. In 1973 Rowley 
found that the Philadelphia chromosome (Ph) was a result of a reciprocal chromosomal 
translocation between the long arms of chromosomes 9 and 22.5 It took another 10 years before 
it was revealed that the proto-oncogene ABL on chromosome 9 and the previously unidentified 
BCR gene on chromosome 22 was involved and that the deregulated Abl tyrosine kinase was 
the pathogenic factor.6 7 8 In 1990 Daley et al reported the first evidence of ability of BCR-ABL 
to transform primary myeloid cells and induce a CML-like disease in mice, which finally 
confirmed that the BCR-ABL and the constitutively active Bcr-Abl tyrosine kinase was the 
underlying pathogenic factor in CML.9 
 
Figure1. The normal Chromosomes 9 and 22, the translocation, and the two derivate chromosomes 9q+ 
and 22q- (Ph).  
Prior to the 1950s, splenic irradiation was the mainstay of CML therapy. The treatment had no 
or minimal effect on survival. In the mid 1950s busulphan became the prevailing palliative 
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treatment of CML, reducing the leukocytosis and splenomegaly. Busulphan was some decades 
later replaced by hydroxyurea (HU) as the treatment of choice, due to less toxicity of the latter. 
Neither drugs affected cytogenetic response or progression to BP resulting in a median survival 
of 3.2 years in the 1970s.10 Until the 1980s, CML was regarded as incurable and inexorably 
fatal.  
In the 1980s it became clear that allogeneic stem cell transplantation (SCT), despite a relatively 
high transplantation-related mortality especially in the early years, could induce long-term 
Philadelphia chromosome negativity. It became the treatment of choice for eligible younger 
patients with access to a donor since it offered a chance of cure. Efforts to extend SCT to all 
patients with CML failed, due to lack of suitable donors and the increased incidence of lethal 
graft-versus-host disease (GVHD).11  The standard therapy for the majority of patients in CML 
chronic phase (CML-CP) in the mid 1980s was recombinant interferon-α (IFN). All studies that 
reported IFN as first line treatment, tested the drug in combination with other agents mostly 
hydroxyurea, low dose cytarabin or both. IFN prolonged life of patients in all ages, but lower 
doses were used in elderly patients. IFN showed promising results in different studies with 10-
year overall survival (OS) of 25-53%12 13 and a median survival of 5-7.5years.14 However, IFN 
therapy was associated with side effects, including fever, chills, muscle pain, asthenia, fatigue, 
that lead to considerably reduced quality of life and problems to maintain the required high 
doses of IFN. 
In 1984 the Swedish CML Study Group was formed, and presented national recommendations 
for the management of patients with CML the same year. Between 1984 and 1989 the Swedish 
CML Study Group randomly allocated patients to treatment with either HU or busulphan. 
Approximately 35% of all patients with newly diagnosed CML (n=179) were included.15 No 
difference in overall or blast crisis-free survival was observed. Patients who underwent 
allogeneic SCT fared significantly better with a median survival of 4.7 years in comparison 
with 3.3 years in patients who did not. As a consequence of the study, younger patients were 
offered SCT. In patients younger than 55 years of age without a donor, the Swedish CML Study 
Group during the 1990s explored combined treatment with HU and IFN followed by one to 
three courses of intensive chemotherapy. Patients who achieved significant Ph reduction and 
negativity underwent high-dose chemotherapy and autologous SCT to further minimize the Ph-
positive clone.16 During the same period (1989 to 1997), the Swedish CML Study Group used 
an intensive chemotherapy protocol in patients in accelerated phase (AP) and blastic phase (BP) 
in an attempt to restore CP, including allogeneic or double autologous (i.e., cells harvested in 
early chronic phase) SCT. The 1-year survival was 70% for allo-geneic SCT/Autologous-
SCT(ASCT) patients (median survival 21 months), 50% in responding patients overall, but only 





1.2  CML – CLINICAL ASPECTS 
1.2.1  Definition, diagnostic criteria, methods and predictors of prognosis. 
CML is a myeloproliferative disease that originates in an abnormal pluripotent bone marrow 
stem cell carrying the Philadelphia (Ph) chromosome and/or the BCR-ABL fusion gene. It is 
found in all myeloid cell lineages, but also in some lymphoid cells,18 although the myelopoiesis 
is dominating. At diagnosis parallel to the malignant clone there is a suppressed normal 
hematopoesis.19,20  
The diagnosis of CML should be suspected based on abnormal blood counts (leukocytosis, 
thrombocytosis), the presence of an enlarged spleen and/or general symptoms such as fatigue, 
weight loss, sweating and is formally diagnosed by  
1) Typical morphological assessment of blood or bone marrow smears  
AND 
2) Detection of the BCR-ABL fusion gene in cells from blood or bone marrow. 
 
Morphology 
The peripheral blood shows increased white blood cell (WBC) counts, due mainly to 
segmented neutrophils and neutrophils in different stages of maturation such as myelocytes, 
metamyelocytes. Basophilia is invariably present and many patients may have eosinophilia as 
well. A low number of myeloblasts are often seen. The platelet count is normal or increased and 
may exceed 1000x109/l. Thrombocytopenia in chronic phase is rare. Most patients have a mild 
anemia. 
The bone marrow shows hypercellularity due to increased numbers of neutrophils and their 
precursors. In chronic phase the blasts are usually fewer than 5%, while 10-19% indicates 
transformation to an accelerated and ≥ 20% to a blastic phase.21 The megakaryocytes are 
characteristically small and have hypolobated nuclei.22 Forty per cent of the patients display an 
increase of reticulin fibers that generally correlates with increased numbers of megakaryocytes, 
enlarged spleen and more severe degree of anemia. 
 
Detection of BCR-ABL fusion gene 
The presence of BCR-ABL can be detected by three different methods;  
1) Chromosome metaphase analysis (chromosome level) shows an elongated chromosome 9 
and a truncated chromosome 22, i.e. the Philadelphia chromosome. Karyotyping ("G-banding” 
or "conventional cytogenetics") is a screening analysis where all chromosomes are evaluated in 
metaphases. Normally 20-30 metaphases are analyzed. Since relatively few metaphases are 
studied the sensitivity is rather low. An advantage of this technique is that additional aberrations 
than Ph chromosome can be identified since the whole genome is analyzed. However, cryptic 
fusions between the BCR and ABL genes can not be detected by karyotyping. 
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Karyotyping is used to measure the response to therapy. The cytogenetic response is associated 
with prognostic significance, why this method is used until a complete cytogenetic response 
(CCyR)= 0% Ph chromosomes, has been achieved.  
 
 2) FISH (Fluorescence In Situ Hybridization) (DNA level) is a targeted analysis, showing the 
gene fusion BCR-ABL. In addition to the typical fusion gene, it is possible to detect cryptic 
fusions. FISH allows the assessment of a larger number of non-dividing (interphase) cells, both 
from peripheral blood23,24 25 26 and bone marrow and is thus more sensitive than chromosome 
banding analysis (CBA). The method can also be performed on cultured metaphase cells, hyper-
metaphase FISH. 27 28 
Probes targeting the ABL and BCR genes are used and nucleated cells are then examined in an 
epiflourescence microscope. The fusion gene will appear yellow. In interphase FISH it is 
recommended that at least 200 cells should be analyzed. The sensitivity for FISH is higher than 
for karyotyping, less than 1 Ph-positive cell per 100 nucleated cells can be detected. The 
method has so far not been used to give prognostic information similar to the degree of 
cytogenetic responses using CBA (i.e. complete cytogenetic response, major cytogenetic 
response etc.) 29 
3) PCR  (Polymerase Chain Reaction) (mRNA level) can be performed on bone marrow and 
blood, usually on blood. Qualitative (RT-PCR) reveals the presence or absence of BCR-ABL 
mRNA. Quantitative  (qRT-PCR), reveals the amount of mRNA. The method is highly 
sensitive and can detect 1 out of 105 transcripts of mRNA. Q-RT-PCR is the only method that 
can measure minimal residual disease (MRD), after the patient reaches normal findings by 
karyotyping (CCgR) or FISH. 30-32 The results of qRT-PCR are expressed as the ratio BCR-
ABL/reference gene (ABL and/or GUS) as a percentage.  A problem with the PCR technique is 
that the methods and results vary between laboratories.  An international scale (IS) has been 
established to make results from different laboratories comparable, by giving each laboratory a 
conversion factor related to a reference laboratory. All over the world laboratories undergo a 
standardization work, in order to express their results according to the IS.31 33 
 
Clinical course 
The natural course of the CML disease is generally divided into three stages/phases. The 
disease can present in any phase but most patients (90%) present in the chronic phase, during 
which mature granulocytes are still produced but with an increased numbers of myeloid 
progenitors in the peripheral blood. This early phase is often asymptomatic. In the absence of 
effective treatment, the disease progresses eventually into the more aggressive phases, AP and 
BP.11 In the pre-TKI era the average duration of the chronic phase was approximately 3-5 
years.34,35 The following shorter AP is a poorly defined phase characterized by an increasing 
number of myeloblasts and basophils in peripheral blood and bone marrow, persistent 
thrombocytosis, and increasing spleen size unresponsive to therapy. In some cases there are 
evidence of clonal evolution. The most common cytogenetic events in the clonal evolution are 
the appearance of +8, +Ph, and i(17q) that denotes the activation of other oncogenes than BCR-
ABL or a deletion of tumour suppressor genes.11 36 There are several definitions for the AP 
including the definitions by European Leukemia Net (ELN),37 World Health Organization 
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(WHO)21 and the American National Comprehensive Cancer Network (NCCN).38 In Sweden, 
the WHO classification from 2008 is the most widely used. The AP is a transition to the final 
blastic phase. Here the percentage of blast cell in the bone marrow or peripheral blood is 
increased to ≥20%, and the blasts can either be of lymphoid or myeloid origin.39-42 Myeloid BP 
is the most common BP 50%, lymphoid 25% and undifferentiated BP in 25%.43 Occasional 
patients have a combined myeloid/lymphoid CML-BP.44 In the CML-BP there is a clear 
maturation stop in the myelopoiesis and the clinical features are more like an acute leukemia. 
Isolated extramedullary proliferation of blasts that can be seen in the skin, lymph nodes, spleen, 
bone or in the central nervous system constitutes a CML-BP, independent of the picture in the 
peripheral blood and the bone marrow. 
           
CML-AP may be made when one or more of the following are present: 
Blasts 10-19% of WBC in peripheral blood and/or of nucleated bone marrow cells 
Peripheral blood basophils ≥20% 
Persistent thrombocytopenia   (<100x109 /l  ) unrelated to therapy or persistent  
Thrombocytosis (>1000x109/l) unresponsive to therapy 
Increasing spleen size and increasing WBC count unresponsive to therapy 
Cytogenetic evidence of clonal evolution 
CML-BP may be made if one or more is present: 
Blasts ≥ 20% of WBC in peripheral blood and/or of nucleated bone marrow cells 
Extramedullary blast proliferation 
Large foci or clusters of blasts in the bone marrow biopsy 
Table 1 .WHO definition of accelerated phase. 
 
Prediction of prognosis 
At diagnosis the most important clinical prognostic factor for survival is to define whether the 
patient is in the chronic, accelerated or blastic phase.21 In chronic phase the risk of progression 
to a more advanced phase can be calculated by the Sokal and Hasford scores, respectively. The 
two scores are calculated in a slightly different way, based on age of the patient, spleen size and 
blood counts. Depending on the results the patients will be designated into one of three risk 
groups; low, intermediate or high.  
The Sokal score uses age at diagnosis, spleen size, platelet count and percentage of blasts in 
blood. It predicts survival of newly diagnosed CML patients treated with hydroxyurea.45 Data 
now indicate that Sokal score also predicts the chance of achieving CCgR and risk of 
progression to AP/BP in patients treated with imatinib.32,46   
The Hasford (Euro) score, is a further development of the Sokal score, predicts survival of 
newly diagnosed CML patients with IFN treatment.47 It is based on data from 1303 patients 
treated within twelve different studies. It is possible, but not yet clearly demonstrated, that 
Hasford score can also be applied to patient groups treated with imatinib. Hasford score is 
calculated based on age, spleen size, platelet count and percentage of blasts, eosinophils and 
basophils in peripheral blood at diagnosis.  
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The EUTOS score is a novel, not yet widely spread score. It is calculated from the percentage of 
basophils and spleen size and predicts outcome of imatinib therapy.48 The score may be used to 
identify CML patients with significantly lower probabilities of responding to therapy and 
survival.  
The risk scoring systems may have lost some of its impact, since the most important individual 
prognostic factor today is the degree and timing of the hematologic, cytogenetic and molecular 
responses.37 49  
 
1.2.2  Epidemiology 
CML is a rare disease that has a reported world-wide incidence of 1.0-1.5 cases per 100 000 
population per year.50 51 The incidence in Sweden during the last 8 year period was 0.8-1.0 per 
100 000, 52 which means that about 90 patients are diagnosed with CML in Sweden annually. 
CML is diagnosed in all ages, but the incidence increases with age. The median age at diagnosis 
in Sweden is approximately 60 years. Males are slightly more affected than females (1.3:1).51,53 
Due to more effective treatment in the last decade, prevalence increases in all Western 
countries.54 No geographical or ethnical differences exist regarding the incidence, but the 
prevalence differs, likely due to differences in management strategies between countries, 
depending of availability of expensive drugs, modern diagnostic technologies and health-care 
system.55 
 
1.2.3  Etiology 
Exposure to benzene and ionizing radiation constitute risk factors. Studies have shown that 
BCR-ABL transcripts can be induced in hematopoietic stem cells by ionizing radiation in 
vitro.56 A sharp increase of the incidence of CML was seen after the atomic bomb in Hiroshima 
194557,58,59. No similar increase in CML incidence has been seen in connection with the 
Chernobyl accident in the Soviet Union in 1986, where the radiation doses were significantly 
lower compared to Hiroshima-Nagasaki.60   
An explanation for the spontaneous appearance of the fusion gene BCR-ABL may be the short 
physical distance between BCR and ABL genes in human lymphocytes61 and CD34 + cells that 
could predispose to translocation between the genes.62,63 The mere presence of the BCR-ABL 
translocation in a hematopoietic cell is not enough alone to  cause CML. It is known that the 
BCR-ABL fusion transcripts of M-BCR and m-BCR type are detected in low frequency among 
30% of healthy individuals.64 65 It is unclear why CML occurs in only a minority of these 
individuals. In healthy subjects the translocation possibly occurs in the terminal portion of 
maturation and is eliminated by the normal immune system. Indirect evidence for the immune 
system effects is that certain HLA types (HLA-B8 HLA-A3) appear to protect against CML.66 
It is also likely that the chromosomal change must occur in a sufficiently primitive 
hematopoietic progenitor cell, in order for the clone to expand. Another possibility is that BCR-
ABL is not the only genetic lesion to induce CML-CP.67 However, in the vast majority of 
patients the etiology of the disease is still unknown and there does not appear to be a hereditary 
facto
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1.2.4  Patophysiology 
Blood cells develop from a multipotent hematopoietic stem cell located in the bone marrow.68 
Normally the maturation from the stem cell into functional blood cells is very well regulated. In 
CML a reciprocal translocation of genes between the long arms of chromosome 9 and 22 has 
occurred in a stem cell.5,11 A part of the Abelson 1 gene (ABL1, hereafter called ABL) on 
chromosome 9 is translocated and forms a fusion gene with a part of the breakpoint cluster 
region gene (BCR), located on chromosome 22. The shorter derivate chromosome 22 carrying 
the BCR-ABL fusion gene, is now called the Ph chromosome t(9;22)(q34;q11).11,69  
The normal ABL proto-oncogene encodes a cytoplasmic and nuclear protein tyrosine kinase 
that has been implicated in processes of cell differentiation, cell division, cell adhesion, and 
stress response.67,70,71 The activity of the ABL gene is negatively regulated by its SH3 
domain,67,72 and deletion of the SH3 domain turns ABL into an oncogene.73 After the t(9;22) 
translocation  the negative regulation of ABL is lost. The new fusion gene, BCR-ABL encodes 
an unregulated, cytoplasm-targeted tyrosine kinase that allows the cells to proliferate without 
being regulated by cytokines. Although the ABL gene product and BCR-ABL fusion protein 
has been extensively studied, the function of the normal BCR gene product is not clear. Parts of 
the ABL gene remains on the derived chromosome 9 and parts of the BCR gene translocates to 
the 9th chromosome, resulting in a ABL-BCR gene. This fusion gene is encoding a protein 
without any known function. 
 
 
Fig 2. After the translocation between chromosomes 9 and 22, the BCR-ABL fusion gene undergoes 
transcription. The resulting BCR-ABL messenger RNA (mRNA) is then translated into the Bcr-Abl 
tyrosine kinase protein, which enhances cell proliferation, adhesion and survival.  
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The site of the breakpoint in the BCR gene differs, but in CML it is almost always in the major 
breakpoint cluster region [M-BCR, BCR-ABL junctions e13a2 (b2a2) and e14a2 (b3a2)]. 
Rarely the breakpoint occurs in the minor breakpoint cluster region (m-BCR e1a2) as in Ph 
positive acute lymphoblastic leukemia (ALL), or in the micro-region (µ-BCR, e19a2) as in 
chronic granulocytic leukemia.11 
The BCR–ABL fusion gene is transcribed into a messenger-RNA (mRNA) which will be 
translated to a protein, a tyrosine kinase called Bcr-Abl, which activates mediators of the cell 
cycle regulation system, leading to CML. The Bcr-Abl protein has different weight depending 
of the different breakpoint in the BCR gene, 190kDa (m-region), 210 kDa (M-region) or 
230kDa, (µ-region) but typically 210 kDa in CML.11 
The Bcr-Abl tyrosine kinase protein is constitutively active, catalyzing the transfer of phosphate 
from ATP to a tyrosine residue on a substrate protein downstream, resulting in the CML 
phenotype, i.e. inhibition of apoptosis, increased proliferation and decreased adhesion to stroma 
cells via effects on Bcr-Abl substrates like CRKL, CBL, RIN, GAP and paxillin and further 
phosphorylation activates intracellular signal pathways like RAS, MYC and STAT.11,74 
The mechanism behind disease progression and clonal evolution, when additional cytogenetic 
aberrations occur, is still largely unknown. Genetic instability as a consequence of the the BCR-
ABL translocation might be one explanation, alternatively, the mechanisms responsible for the 
translocation might trigger the changes leading to progression of the disease.55 
Five to 10% of CML patients have a variant translocation, which means that one or two 
additional chromosomes are involved in the 9:22 chromosomal translocation. All chromosomes 
have been described as participating in these variants, as an example t(3:9:22).75,76  
 
1.2.5  Clinical signs and symptoms 
About 20-40% of the CML patients are asymptomatic at diagnosis.51 The disease is quite often 
detected at a routine medical examination. Others have symptoms like fatigue, sweats, weight 
loss and abdominal fullness. Sometimes symptoms caused by the large number of circulating 
leukocytes are seen eg. visual disturbances (due to vascular effects, including bleeding in the 
fundus of the eye), pain in the left flank  (due to splenic infarction or enlarged spleen) and 
priapism.  
In CML-CP, the peripheral blood shows an increasing amount of both mature and immature 
leukocytes together with mild anemia and sometimes increased number of platelets. Atypically 
the disease presents in CML-AP or CML-BP, without a previously detected CP. The more 
advanced phases of CML are generally accompanied by worsened performance status and by 








Blood count    
Reference 
values 
B-Hb (g/l)   105 134-170 
B-Platelets (109/l)  694 145-348 
B-Leukocytes (109/l) 124 3.5-8.8 
 B-Neutrophil granulocytes 47 1.8-7.5 
 B-Eosinophil granulocytes 2.5 0.04-0.4 
 B-Basophil granulocytes 3.7 0-0.1 
 B-Lymphocytes 9.9 2.9-4.5 
 B-Monocytes 9.9 0.1-1.0 
Immature myeloid cells     
 B-Band-formed  granulocytes 17.4 0 
 B-Metamyelocytes 8.7 0 
 B-Myelocytes 14.9 0 
 B-Promyelocytes 5.0 0 
 B-Blasts   3.7 0 
 B-Erythroblasts 1.2 0 
Table 2. Typical full blood count in a newly diagnosed CML-CP patient. 
  
1.2.6  Treatment   
Tyrosine Kinase Inhibitors 
With improved understanding of the molecular mechanism involved in CML, the development 
of targeted therapies, such as tyrosine kinase inhibitors (TKI) has gradually improved. TKI 
inhibit the Bcr-Abl protein activity, thus stopping the leukemic phenotype. The first TKI for 
CML, imatinib mesylate was a major breakthrough in CML treatment. The large phase 3 
clinical trial International Randomized IFN versus STI571=imatinib mesylate (IRIS) for newly 
diagnosed CML-CP patients started in 2000. The superiority of imatinib over IFN soon became 
obvious. After 12 months of treatment 69% of the imatinib treated patients had achieved CCyR 
compared to 7% in the IFN group.77 After 6 years of treatment the OS was 88% (95% when 
only CML related deaths were considered) in the imatinib arm. Since a majority of the patients 
(65%) randomized to the IFN arm, crossed over to the imatinib arm mainly due to intolerance 46 
it is difficult to correctly compare data between the two arms. However, in the British CML III 
study the 6-year OS was only 5% for patients treated with the IFN.78  At a median of 8 years of 
follow up of the IRIS trial, the estimated OS of all patients randomized to receive imatinib was 
85%. When only CML-related deaths was considered the figure was 93%.79   
Imatinib and later generations of TKI have improved the prognosis for CML patients in all 
disease phases, but most particularly for patients in CML-CP.80 TKI induce a much faster 
reduction of BCR-ABL transcript levels than previously available drug therapies. Today TKI is 
formally approved as first line treatment for CML-CP in all ages. Currently there are three TKI 
approved by European Medicines Agency (EMA) and Food and Drug Administration (FDA) as 
first-line treatment in CML; imatinib, nilotinib and dasatinib. Additional TKIs (bosutinib and 
ponatinib) are currently being evaluated in clinical trials. 
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A recent French study has shown that approximately 40% of 100 imatinib treated patients with 
a deep molecular response could discontinue treatment, without any signs of recurrent disease 
within 2-3 years.81,82 Since 2nd generation TKIs as first line treatment seem to generate a larger 
number of patients with deep molecular response, is possible that more CML-CP patients can 
discontinue the treatment in the future. 
Although imatinib has dramatically increased survival for CML patients in CP the outcome of 
patients in more advanced phases has not been as successful. A treatment effect can be seen, but 
is usually transient. TKIs may play a role as a bridge to allogeneic SCT for patients who 
progress to BP. For patients progressing to AP during imatinib treatment a switch to a 2nd 
generation TKI may revert the disease into the CP. 
 
Imatinib (Gleevec® or Glivec®) is a small molecule, created by using the structure of the ATP 
binding site of the ABL protein kinase as a template. It binds to the adenosine triphosphate-
binding (ATP) site of Abl, thereby keeping the protein in an inactive form, thus inhibiting the 
phosphorylation of substrate and subsequent blocking the activity of the Bcr-Abl tyrosine 
kinase. The transmission of the oncogenic signal to the nucleus is by this interrupted and 
thereby the malignant transformation, since unphosphorylated Bcr-Abl tyrosine kinase is 
inactive.83 Imatinib is  relative specific for Bcr-Abl tyrosine kinase but also active against 
platelet-derived growth factor (PDGF) receptor84,85 and c-KIT receptor kinase.86 In Sweden 
imatinib was approved for clinical use in 2001 and was the only TKI approved for newly 
diagnosed CML patients until 2010. The most frequent side-effects are oedema, muscle cramps, 
rash, nausea, diarrhoea, and hepatotoxicity.87 88 89 
Imatinib is also used in the treatment of gastrointestinal stroma tumor (GIST)90 91 in hypereo-
sinophilic syndrome (HES)92 and chronic eosinophilic leukemia (CEL)93 with FIP1L1-PDGFRα 
rearrangement,92,94,95 (PDGFR) gene, in unresectable dermatofibrosarcoma protuberans 
(DFSP)96 and in Ph positive acute leukemias, mainly in ALL. 97,98 99 100 However, except for 
newly diagnosed CML-CP patients, there are no controlled trials demonstrating a clinical 
benefit or increased survival for these diseases. 
 
Dasatinib (Sprycel®) a second generation TKI, is a dual Abl/Src kinase inhibitor that binds to 
Abl kinase domain irrespective of the configuration of the activation loop. Dasatinib inhibits a 
lot more tyrosine kinases than imatinib and nilotinib. Dasatinib was approved in 2006 for CML 
(CP, AP and BC) with resistance or intolerance to imatinib and to Ph positive ALL in resistance 
or intolerance to prior therapy. It was approved for treatment of newly diagnosed CML patients 
in 2010 but the Swedish The Dental and Pharmaceutical Benefits Agency (TLV) does not 
reimburse the drug as first line treatment. Consequently it is not used beyond clinical trials as 
first line drug.  
The DASISION (Dasatinib vs Imatinib Study in Treatment–Naïve CML patients) study in 
newly diagnosed patients, has shown a significantly superior response for the dasatinib vs. 
imatinib with a major molecular response (MMR) rates at 3 years of 68% vs. 55% treated.101 
The rate of transformation to AP or BP was numerically (but not statistically significantly) 
lower for dasatinib: 4.7% vs. 6.7%.101 Treatment with dasatinib cause pleural effusion in 14-
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26% of the patients 102,103 104 105 106 107 which seems more frequent in patients with previous 
cardiovascular/ pulmonary disease, and autoimmune diseases.108  
 
Nilotinib (Tasigna®) a second generation TKI derived from imatinib, is a selective Abl inhibitor 
that binds to the inactive/closed conformation of the Abl kinase that also inhibits c-KIT, ARG, 
PDGFα and PDGFβ. Nilotinib was approved in 2007 for treatment of CML patients with 
resistance or intolerance to imatinib and was in 2010 approved for newly diagnosed patients 
since the large randomized ENESTnd (Nilotinib Efficacy and Safety in Clinical trial-Newly 
Diagnosed Patients) study showed that nilotinib compared to imatinib resulted in deeper and 
faster short term treatment responses .109,110 The cumulative rates of MMR by 3 years was 70% 
to 73% with nilotinib (two different doses) and 53% with imatinib, combined with a 
significantly lower rate of transformation to AP or BP was observed, 2.1-3.2% vs 6.7%, 
respectively.111 Nilotinib may cause pancreatitis (about 1%), liver (5-10%), lipase increase 
(about 10%) and cause hyperglycaemia.112  
 
Imatinb	   ABL,	  ARG,	  BCR-­‐ABL,	  KIT,	  PDGFR,	  DDR1/2,	  NQO2	  
Nilotinb	   ABL,	  ARG,	  BCR-­‐ABL,	  KIT,	  PDGFR,	  DDR1/2,	  NQO2	  
Dasatinib	   ABL,	  ARG,	  BCR-­‐ABL,	  KIT,	  PDGFR,	  DDR1/2,	  SRC,	  YES,	  FYN,	  LYN	  	  
	   HCK,	  LCK,	  FRG,	  BLK,	  FRK,	  CSK,	  BTK,	  TEC,	  BMX,	  TXK,	  ACK,	  
	  	   ACTR2B,	  ACVR2,	  BRAF,	  EGFR/ERBB	  ,EPHA2,	  EPHA3,	  EPHA4	  
	  	   EPHA5,	  FAK,	  GAK,	  GCK,	  HH498/TNN13K	  ILK	  LIMK1,	  LIMK2	  
	  	   MYT1,	  NLK,	  PTK6/Brk,	  QIK,	  QSK,	  RAF1,	  RET,	  RIPK2,	  SLK,	  
	  	   STK36/ULK,	  SYK,	  TAO3,	  TESK2,	  TYK2,	  ZAK	  
Table 3. Tyrosine kinase “targets” of imatinib, nilotinib and dasatinib.113,114 
 
Treatment objectives 
Today the key objectives of front-line therapy in CML chronic phase are to 
i)  Prevent progression to the advanced phases (AP and BP)  
ii) Maximize achievement of CCyR and MMR which gives the patient a platform to achieve 
CMR and thereby a possibility of drug cessation.  
There are three clinical milestones (interim targets) in the treatment response of CML-CP 
(Table 4) 
1) Complete hematologic response (CHR) 
2) Complete cytogenetic response (CCyR) 
3) Deep molecular response, i.e. achieving major molecular response (MMR) and “complete 
molecular response” (CMR, signifying non-detectable transcripts, normally <MR4.0 – MR5.0). 
 
 The response to TKI treatment is generally fast, with normalization of leukocytosis/ 
thrombocytosis within weeks, followed by a gradual reduction of Ph positive cells in blood 
and bone marrow until achieving CCyR and MMR/CMR. To guide the physicians European 
Leukemia Net (ELN) and other organizations give valuable recommendations, which among 
other things specify treatment goals at certain time points.37,49  
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 In trials, second generation TKIs as first line treatment seem to give a more rapid treatment 
response and with fewer patients progressing to AP and BP, compared to imatinib, but so far, 
no overall survival benefits have yet been reported. 
 
 
Definitions of treatment response 
Hematologic response   
Complete (CHR): B-WBC <10 109/l 
  B-Basophils< 5% of WBC 
  B-Platelets <450 109/l 
  No leukocyte precursors in peripheral blood 
  No palpable spleen 
Cytogenetic response  (% Ph positive metaphases) 





Molecular response BCR-ABL % International scale (IS) 
Major   (MMR, 3.0 log 
reduction) ≤0.1 
MR4.0  (4.0 log reduction) ≤0.01 
MR4.5  (4.5 log reduction) ≤0.0032 
MR5.0  (5.0 log reduction) ≤0.001 
Table 4. Definitions of treatment response. 
 
Time Optimal Suboptimal Failure Warnings 
At diagnosis       High risk. CCA/Ph+ 
3 month 
CHR and at least minor 
CR  No CgR Less than CHR   
6 month At least PCgR Less than PCgR No CgR   
12 month CCgR PCgR Less than PCgR Less than MMR 
18 months MMR Less than MMR Less than CCgR   
Any time 
Stable or improving 
MMR Loss of MMR 
Loss of CHR or 
CCgR CCA/Ph- 
    Mutations A Mutations B   
      CCA/ Ph+   
Table 5. Definitions according to ELN, of optimal and suboptimal response, failure and warnings for 
previously untreated patients with early chronic phase CML, treated with imatinib at certain time points.  
Mutation A= Still sensitive to imatinib. Mutation B= Poorly sensitive to imatinib. CCA= Clonal 
chromosome abnormalities. 37,49 
  
Treatment in AP and BP 
Patients diagnosed in AP may initiate treatment with a 2nd generation TKI. They should be 
carefully monitored, and if the patients do not reach the criteria for CP, allogeneic SCT should 
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be considered. For imatinib treated patients progressing to AP a switch to a 2nd generation TKI 
or SCT is needed. 
For patients diagnosed in or that have progressed to BP, the prognosis is very poor. If CML is 
diagnosed in BP the patients should start TKI treatment in combination with ALL- or AML- 
like chemotherapy (depending on lymphoid or myeloid phenotype) and be considered for 
allogeneic SCT as soon as possible. If progressing to BP during imatinib treatment the patients 
should be prepared for allogeneic SCT if possible, and a switch to high dose dasatinib is then 
preferred (unless mutations resistant to dasatinib) to optimize the conditions for SCT. AML - or 
ALL–like chemotherapy could be given before transplantation.  
The response to TKI in BP is expected to be transient. Allogeneic SCT has a curative potential 
for CML and the best results are achieved for patients transplanted in CP.115-118 SCT in overt BP 
is not recommended.116   
Treatment failure 
If imatinib treatment of a CML-CP patient does not meet the ELN criteria for “optimal” 
response at a certain time point (see table 1), the response may be regarded as “suboptimal” or 
as a “failure”. There are several explanations for not achieving optimal response. Both BCR-
ABL dependent and independent mechanisms have been suggested; poor compliance, reduced 
bioavailability, mutations in the Bcr-Abl tyrosine protein pocket, clonal evolution or 
resistance to the drug etc. When treatment failure is a fact, a change of treatment is needed. 
Both dasatinib and nilotinib have been shown to have clinical activity in CML patients with 
intolerance or resistance to imatinb.119-123 Another options is allogeneic SCT. 
In the case of BCR-ABL independent factors, a dose escalation of imatinib may be successful. 
There are currently about 100 known mutations, rendering imatinib therapy suboptimal or 
failing. In most cases, 2nd generation TKI can overcome this.124,125 Nilotinib is sometimes a 
better choice than dasatinib, or vice versa, related to specific mutations. Dasatinib thus seems to 
be more effective than nilotinib in the presence of BCR-ABL mutations such as Y253F/H, 
E255K/V, F359C/V while in the presence of Q252H, V299L and F317L, nilotinib is preferable 
to dasatinib.126 Only one mutation, T315I (threonine 315 isoleucine) is completely resistant to 
imatinib, dasatinib and nilotinib.127 However, ponatinib, a multi-targeted tyrosine kinase 
inhibitor, has in an on-going clinical trial shown efficacy against this mutation.128 The AP may 
after a switch of TKI be induced to revert into the CP. In BP the effect of TKIs is very limited. 
If any effect, it is not durable, but can act as a bridge to allogeneic SCT, which is the only 
treatment offering long-term survival for patients in BP.129 
 
Surrogate markers for long-term outcome 
CCyR, MMR and CMR are the therapeutic goal in treatment of CML-CP in order to minimize 
the risk of transformation into advances phases. For many years, the main goal of treatment was 
to achieve CCyR, since studies had shown that CCyR was associated with survival benefits.130-
132 With the introduction of imatinib treatment, a majority of the patients achived CCyR. Many 
had an even better response, major molecular response (MMR), which gave further improved 
OS 46,49,130,131,133,134 compared to patients with CCyR but without MMR.135 Furthermore, 2nd 
generation TKI (dasatinib and nilotinib) as first line treatment seem to give an even deeper and 
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faster response, and the proportion of patients achieving MMR is higher at 12 months than with 
imatinib. 109,136,137 Today the IRIS study has given the clinicians more than 10 years of 
experience regarding imatinib treatment. At 5-year the cumulative incidence of CCyR in the 
imatinib arm was 87%.130 At that time 93% of the patients had not progressed to the accelerated 
or blastic phases. The estimated 5 year OS was 89%.130  However at 5 years 31% of the patients 
in the IRIS study had discontinued imatinib treatment and were censored.131 Clinical trials using  
“intention to treat” criteria may be difficult to interpret as for instance in the IRIS study. The 
achieved OS is not only reflecting imatinib treatment, but eventually also second line TKI 
and/or allogeneic SCT, thus the OS in the IRIS study is likely overestimated, reflecting only 
imatinib treatment. 
However, achieving CCyR and MMR seems to give the patients long-term event free and 
overall survival, but there is also a time aspect when the goals are achieved. Reducing the 
tumour load is important to reduce the risk of progression to more advanced phases. Having 
achieved CCyR and MMR the annual risk of progressing is low. For example, in the IRIS study 
no patient that had achieved MMR at 12 months subsequently progressed into AP or BP in the 
5-year follow-up130. Detailed recommendations are available for monitoring and timing of 
treatment goals, provided by groups and individual centers. In Sweden the national 
recommendations138 are used which are similar to the guidelines of ELN. To further improve 
the outcome, we probably need to act earlier in the disease process, at an earlier time than 
guidelines advise us today.  
 
1.3  SWEDISH POPULATION REGISTRIES  	  
Since 1947 all Swedish citizens are given a unique identification code at birth. For each 
individual, date of death is centrally registered in the nation wide “Cause of Death 
Registry”139.  Furthermore, every physician, pathologist and cytologist are obliged by law to 
report occurrence of cancer to the population-based national wide “Swedish Cancer 
Registry”140 established in 1958. Through these high quality registers it is possible to follow 
patients from the date of cancer diagnosis to death. The Swedish CML Registry, established in 
2002, collects information once a year from physicians treating CML patients throughout the 
course of the disease. The registry is unique, with nearly all CML cases in Sweden included. 
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To improve management of patients with CML by  
i) identifying early biological markers linked to long-term clinical outcome of 
imatinib treatment   
and  
ii) establishing population-based survival data including health economic aspects 




I.   
To evaluate the impact of early reduction of disease burden on long-term outcome (i.e. 
landmark analysis) in imatinib treated patients. 
 
II.   
To evaluate the effect of imatinib treatment on neutrophil leukotriene signaling and assess its 
possible role as a clinical marker of CML treatment response. 
 
III. 
To define real life outcome of patients with CML in Sweden during four decades and to relate 
the survival patterns to imatinib treatment and other management strategies. 
 
IV.  
To evaluate health economic aspects of real life treatment of CML in Sweden, comparing 
imatinib with previous and alternative therapeutic strategies.  
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3  STUDY OF PROGNOSTIC FACTORS-LANDMARK 
ANALYSIS  (I)  
 
3.1  METHODOLOGICAL ASPECTS 
Imatinib has dramatically improved the outcome in CML-CP, but still some patients continue to 
respond sub optimally or become resistant to imatinib. These patients need alternative treatment 
with an early switch to 2nd generation TKI or allogeneic SCT. Standard dose imatinib (400mg 
q.d.) has been reported to induce CHR in the majority of patients and CCyR in 69% within 12 
months of treatment, but a minority of the patients still does poorly. In the IRIS study, 34% of 
the patients had discontinued their initial imatinib therapy at 5 years because of different 
reasons, mostly intolerance or resistance. Seven percent of the IRIS study patients had 
progressed to AP or BP within 2 years.130 The risk of progression seems to peak during the first 
year of treatment, before the tumour burden radically has been decreased. Apparently, we need 
to act early of signs of non-optimal response, to improve outcome in imatinib treated patients.  
CBA has for many years been the gold standard for evaluating treatment effects and to reach a 
status of non-detectable Ph-chromosomes (CCyR) by 12 months, has been regarded as one of 
the treatment goals. Since 30% of the patients do not reach that goal it is of interest to early 
identify patients having an increased risk of progression of the disease.  
In an attempt to identify markers of early non-responders, we followed 45 newly diagnosed 
CML-CP patients initiated on imatinib treatment at standard dose at Karolinska University 
Hospital. We evaluated the treatment responses by repeated FISH, PCR and cytogenetics 
assessments initially at 3 months intervals. 
 
3.1.1 Cytogenetic Banding Analysis (CBA)
Conventional cytogenetic analyses of bone marrow samples were performed at the Department 
of Clinical Genetics, Karolinska University Hospital. All investigations were done using 
standard G-banding technique and followed the rules of International System for Human 
Cytogenetic Nomenclature, ISCN. Cytogenetic response evaluations were regularly based on 
full analysis of at least 20 metaphases. Of a total of 257 samples in this study, 246 contained 20 
or more metaphases, with a median of 29 metaphases analysed per sample. 
 
3.1.2 Fluorescence In Situ Hybridization (FISH)  
DNA-probes directed against the BCR and ABL genes are added to a smear of blood or bone 
marrow cells and are analyzed in an epifluorescence microcope. The reliability of FISH is 
largely dependent on the quality of the DNA probe used.141,142,143 Different probes show 
different signal patterns.144 The Extra Signal Dual Color Translocation Probe-FISH (ES-FISH) 
reduces the number of falsely BCR-ABL positive cells, compared to the earlier used Dual Color 
Single Fusion Translocation Probe-FISH (S-FISH).143,145 Our control studies showed that the 
ES probe, in our hands, had high sensitivity and specificity, similar to the Dual Color Dual 
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Fusion translocation Probe (D-FISH).146 One disadvantage with ES-FISH compared to D-FISH 
is that Ph-clones with minor deletions of the long arm of chromosome 9 can be missed because 
these aberrations will give the typical signal pattern 1G1O1F. 
In our study we performed interphase FISH on unseparated nucleated cells on bone marrow 
smears, using an extra signal dual-color DNA probe (LSI BCR-ABL ES Dual Color 
Translocation probe, Vysis, IL). The probe is a mixture of the LSI ABL probe labeled with 
spectrum orange and the LSI BCR probe labeled with spectrum green. The spanning ABL 
probe is approximately 650kb extending from an area centromeric of ASS gene well telomeric 
of the last ABL exon. The spectrum green BCR probe is approximately 300 kb beginning 
between BCR exons 13 and 14 (M-BCR region) A cell lacking the BCR-ABL fusion gene will 
exhibit a two orange and two green signal pattern (2O2G). In a cell carrying the fusion gene one 
green (native BCR) one large orange (native ABL), one smaller orange (rest signal of ABL on 
the derivate chromosome 9) and one fused green/orange (BCR-ABL) (2O1G1F). 





Figure 3. A BCR-ABL positive cell with the typical ES probe signal pattern 2OIGI.   
(Photo Ingrid Arvidsson) 
 
 
Control studies for FISH 
Bone marrow smears from nine Ph-negative controls were analyzed using the ES probe. In each 
case 500 cells were scored. The mean percentage of “not true” BCR-ABL positive cells among 
these controls was 0.031% (SD 0.075%) For the purpose of our study  (I) we decided to define 
the cut-off level for a “true” positive sample to ≥0.25% (mean +2.576xSD). 
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Further cytospin preparations from the CML cell line K562 were used as positive controls. All 
(100%) of 2500 K562 cells examined with the ES-probe depicted the typical fusion pattern 
(2O1G1F).  
To compare DS-FISH with ES-FISH, we analyzed nine patient samples with both probes. We 
found a strong correlation (r= 0.87;p= 0.0003). 
 
3.1.3 Quantitative reverse-transcriptase Polymerase Chain Reaction (qRT-PCR)
The Department of Clinical Genetics, Karolinska University Hospital, Stockholm, performed 
the PCR analysis. For samples prior to October 2008 peripheral blood mononuclear cells were 
separated by the Ficoll-Paque TMPLUS (GE Healthcare, UK) and total RNA was isolated 
using Trizol® reagent (Invitrogen, Carlsbad). From October 2008 and onwards, total blood 
leukocytes were used for RNA isolation. RNA (1µg) was reverse-transcribed into cDNA as 
described elsewhere using pd(N)6 random hexamer (GE Healthcare, UK) and M-MLV 
enzyme (Invitrogen, Carlsbad).147 ABL and GUS were used as control genes to correct for 
variations in RNA quality and quantity.148 The BCR-ABLp210 and BCR-ABLp190 mRNA 
transcripts were assessed by quantitative real-time RT-PCR, as described previously.148,149 
ABL and GUS were used as reference genes. In this studies, we consequently expressed the 
amount of BCR-ABL transcript as a ratio of BCR-ABL copy number relative to 100 ABL 
copies, since the IS not yet was established in our laboratory at that time. 
3.1.4  Statistical methods 
The probabilities of OS and event free survival (EFS), where events were defined as response 
loss, progression or death, in line with ELN recommendations.49 OS and EFS were calculated 
using Kaplan-Meier method150 according to the intention-to-treat principle. The association 
between early determinations of BCR-ABL or Ph-expression, as assessed by the three different 




3.2  RESULTS AND DISCUSSION 
The median follow up was 58 (range 15-115) months. Within 12 months of treatment 80% 
achieved CCyR and 42% MMR. Corresponding figures at 24 months were 97 and 84%. After 3 
months of treatment the median BCR-ABL expression was 9.8 (range 0-95)% according to 
FISH and 16.0 (range 0-100)% according to PCR. Corresponding figures for 6 months were 
0.25 (range 0-65)% for FISH, 1.2 (range 0-85)% for PCR and 0 (range 0-100)% for CBA.  
Four patients (8.8%) progressed to AP within 16 months. One patient later progressed into BP 
after initially having achieved CCyR. 
In a landmark analysis, an early favourable response, defined as < 10% BCR-ABL positivity by 
FISH after 3 month of treatment, was identified as a predictive marker of an improved long-
term clinical outcome. Thus of evaluable patients, 51% achieved this response. Ninety-five per 
cent of such responders reached CCyR within 12 months and 100% had an event-free survival 
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at 48 months as compared to 67 and 65%, respectively, of patients with higher (≥ 10%) BCR-
ABL positivity at 3 months. 
 
 
  BCR-ABL positive cells by FISH BCR-ABL mRNA by PCR 
  <10% ≥10% P-value <10% ≥10% P-value 
3-month landmark   
 
    
 
  
CCyR at 12 months 18/19 (95%) 12/18 (67%) 0.042 11/12 (92%) 11/15 (73%) 0.342 ns 
EFS at 36 months 19/19 (100%) 12/18 (67%) 0.008 10/11 (91%) 11/16 (69%) 0.350 ns 
EFS at 48 months 19/19 (100%) 11/17 (65%) 0.006 9/10 (90%) 11/16 (69%) 0.350 ns 
6-months landmark   
 
    
 
  
CCyR at 12 months 21/24 (88%) 1/4 (25%) 0.022 23/27 (85%) 5/8 (63%) 0.312 ns 
EFS at 36 months 21/24 (88%) 2/5 (40%) 0.046 24/27 (89%) 7/8 (87%) 1.0 ns 
EFS at 48 months 21/24 (88%) 2/5 (40%) 0.046 21/24 (88%) 6/7 (86%) 1.0 ns 
12-months landmark   
 
    
 
  
EFS at 36 months 17/18 (94%) 0/3 (0%) 0.003 31/34 (91%) 0/2 (0%) 0.016 
EFS at 48 months 17/18 (94%) 0/3 (0%) 0.003 27/30 (90%) 0/2 (0%) 0.020 
 
Table 6. Number of patients with CCyR at 12 months, EFS at 36 months and EFS at 48 months, related 
to responses at 3 and 6 months assessed by FISH and PCR. 
 
We showed that significantly more patients with a reduction of the malignant clone to <10% at 
3 months of imatinib treatment achieved CCyR within 12 months compared to those that failed 
to reach this level of reduction. They had also a significantly better EFS both at 36 and 48 
months compared to patients with BCR-ABL ≥10% by FISH at 3 months. This finding is 
consistent with other research groups,151,152 using the qRT-PCR method, observing that patients 
with PCR levels ≥10% at 3 month are likely to respond poorly on imatinib therapy. Marin et al 
found that patients with transcript levels of more than 9.84% (n = 68) at 3 months had 
significantly lower 8-year probabilities of OS (56.9% v 93.3%; p <0.001), progression-free 
survival, cumulative incidence of CCyR, and CMR than those with lower transcript levels.151 
Hanfstein et al found persistence of BCR-ABL transcript levels >10%, according to the IS at 3 
months, to separate a high-risk group (28% of patients; 5-year OS: 87%) from a group with 1-
10% BCR-ABL.152 In contrast, when we performed landmark analysis on our patient cohort 
with PCR, we did not observe the same predictive value as with FISH. The fact that we did not 
use IS in our study may explain why we did not find the same predictive value with PCR<10% 
as other groups have. Although PCR has become the dominating method for monitoring TKI 
treatment, particularly to detect minimal residual disease (MRD), the technique can be 
inconsistent with considerable intralaboratory and interlaboratory variations. Thus, this will be a 
minor problem when laboratories have harmonized the PCR standard to the IS. Despite this, 
many physicians do not have access to laboratory service with the semi-quantitative PCR 
method. The well-established FISH method could then be of great value. 
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In our study four patients (8.8%) progressed to AP within 16 months using the WHO 
classification, which is slightly more than is reported in the IRIS trial where 7.9% progressed 
within 18 months.77 However, in the IRIS study, a different definition of AP and BP was used. 
In the IRIS study definition of AP was ≥15% blasts in peripheral blood or bone marrow and for 
BP ≥30% blasts, compared to 10-19% and ≥20% respectively, in the WHO classification. If 
WHO classification would have been used in the IRIS study, probably more patients would 
have been considered to have progressed to AP or BP. 
 
All of our four patients had clonal evolution in their Ph+ cell clones. Thus, undoubtedly, they 
had progressed to AP. They were all scored as Sokal intermediate risk at diagnosis. Two of 
these four patients regained chronic phase after treatment with second generation TKI, while the 
remaining two died. All patients with Sokal high-risk score achieved CCyR within 12 months, 
although high-risk patients in general have an increased risk of progression.130,153 154 
 
Our data, even though based on a limited patient cohort, indicate that FISH can effectively be 
used in the early assessment of remaining Ph-positive cells to identify patients at risk for a long-
term non-optimal response to imatinib. In clinical practice; sufficient data presently indicate that 
a change of treatment to 2nd generation TKI should be considered if BCR-ABL levels persist 
above 10% after 3 months of treatment with imatinib, as measured with PCR or FISH or PCR. 
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4 STUDY OF PROGNOSTIC FACTORS - LEUKOTRIENE 
SIGNALING (II)  
4.1  BACKGROUND 
Leukotrienes (LTs) are a family of lipid mediators derived from arachnoid acid with important 
signaling molecules in inflammatory and allergic conditions.155-158,156-159 Leukocytes can form 
various types of leukotrienes (hence their name) via an initial conversion of arachnoid acid to 
LTA4, a reaction mediated by the 5-lipoxygenase (5-LO) enzyme. Members of our group have 
previous reported data indicating a role for certain leukotrienes also in CML. Thus, we have 
found that the bioactive cysteinyl-containing leukotriene C4 (LTC4) can stimulate normal 
human myelopoiesis160 and that myeloid cells from CML patients have a markedly increased 
capacity to synthesize LTC4.160,161 Moreover, neutrophils from CML patients were noted to 
possess significant leukotriene C4 synthase (LTC4S) expression and activity, while this is not 
the case for normal neutrophils.162,163 Recently, the 5-LO was suggested as a crucial growth 
regulator for leukemia stem cells (LSC) in CML, since gene expression profiles using DNA 
micro array technique identified Alox5, the gene encoding 5-LO, as highly and selectively 
expressed in LSC. Blocking the Alox5 activity impaired LSC function and prolonged survival 
in mice  with CML.164 These data indicate a role for Alox5 and LTC4 in CML leukemogenesis.  
In this study we examined and followed the response of imatinib treated CML-patients over 
time, to analyse whether imatinib could regulate neutrophil LTC4S expression and activity in 
vivo and if so, whether such changes were paralleled by changes in the expression of BCR-
ABL. If so, a normalization of neutrophil LTC4S and/or activity might be used as a novel 
indirect biomarker of early treatment efficacy. Furthermore, we also aimed at estimating the  
LTC4 production in vivo, by assessing urinary excretion of the LTC4 metabolite LTE4 in 




Fig 4. Enzymatic biosynthesis of leukotrienes from arachidonic acid. 5-LO= 5-lipoxygenase. 
LTC4S=Leukotriene C4 synthase. 
 
 
4.2  PATIENTS AND METHODS 
We sequentially studied the activity and expression of LTC4S in neutrophils from CML patients 
subjected to imatinib treatment, and related these data to the parallel development of BCR-
ABL-expression. A total of eleven CML-CP patients, three newly diagnosed and eight with 
previous IFN therapy, were assessed. Blood samples were drawn before start of imatinib 
therapy and then after 2 weeks, 1, 4, 6 and 9 months of treatment. Peripheral blood CD16+ 
neutrophils were isolated using magnetic cell sorting (MACS). Their LTC4S activity assessed 
(i.e. Formation of LTC4 from LTA4) as measured by high performance liquid chromatography, 
(HPLC) and LTC4S expression determined at the protein (immunoblot) and mRNA (RT-PCR) 
levels. In parallel, Ph-chromosome expression was assessed by bone marrow cytogenetics and 
by performing FISH on smears of peripheral blood identifying and specifically scoring 
neutrophilic granulocytes by a combined May-Grünwald-Giemsa staining and regular FISH 
technique cells, which makes it possible to allocate specific chromosomal aberrations (in this 
study BCR-ABL) in morphologically defined cells.165,166 
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4.2.1  Statistical methods  
The two-sided Student`s test for unpaired samples was employed to compare mean values of 
LT production in the different cell fractions
 
4.3  RESULTS AND DISCUSSION 
We demonstrated that in vivo-treatment of CML patients with imatinib led to a normalization of 
the aberrant LTC4S expression and activity. In general, this normalization occurred in parallel to 
a reduced DNA-expression of BCR-ABL, but the time courses of these changes were different. 
Already after 14 days of imatinib treatment we found a significant decrease of LTC4S activity 
in the neutrophils while the BCR-ABL expression remained unaltered in these cells at the same 
time point. We propose that a block of p210/Bcr-Abl protein activity in neutrophils by imatinib 
blocks down-stream 5-LO/Alox5 activity and thereby LTC4S and LTC4 formation. This can 
occur in CML cells that still express the Ph chromosome. Later, when imatinib treatment has 
resulted in replacement of Ph-positive CML cells with normal Ph-negative cells, LTC4S activity 
remains low or non-detectable while FISH and cytogenetics show no or low BCR-ABL 
expression.  
Thus, it is possible that analyses of neutrophil LTC4S and/or LTC4 expression may serve as 
early biomarkers of initial phase clinical imatinib response in CML-CP. Although TKIs are the 
standard treatment of CML today, resistance to these drugs remains a problem for certain 
patients. Targeting complementary, aberrant signaling pathways down-streams of or parallel to 
Bcr-Abl tyrosine kinase may provide a constructive option. 
Furthermore, urine samples from 23 CML-CP patients were analyzed and compared to urine 
samples from 18 healthy controls to look for differences in LTE4 excretion, which is considered 
to represent the combined in vivo formation of the LTC4, LTD4 and LTE4, the cysteinyl LTs 
(cysLTs) in humans.167 Notably, a significantly higher level of LTE4 was observed in the CML 
group. This indicates indeed a higher in vivo production of LTC4 in the leukemia patients and 
further supports a pathophysiological role for the cysLTs in CML.  
The recent results by Chen et al demonstrating that blocking the 5-LO with the asthma drug 
zileuton inhibited the leukomogenesis in CML induced mice are consistent with our findings of 
a relationship between 5-LO, LTC4 and BCR-ABL in CML. An ongoing clinical study in USA 
is examining the effect of combining the 5-LO inhibitor zileuton with imatinib in newly 








Figure 5. LTC4S activity in CD16 (+) neutrophils (left panel) and the parallel occurrence of BCR-ABL, 
investigated by FISH (right panel) from CML patients before, after 7 and 14 days of treatment with 
imatinib. The lines represent individual patients and the bars show mean+/- SEM (n=4) of experiments 















5  POPULATION-BASED STUDIES OF SURVIVAL IN CML (III) 
5.1  PATIENTS AND METHODS 
Our aim was to assess trends in survival, among all patients diagnosed with CML in Sweden, 
regardless of clinical trial enrollment, during a 36-year period. In the 1970s, at the start of the 
study period, busulphan was the dominating therapeutic agent. It was followed by a more 
widespread use of hydroxyurea and the introduction of IFN and allogeneic SCT. Most 
importantly, imatinib was available in study protocols from 2000 and it was approved by the 
Swedish Medical Products Agency (MPA) in November 2001 for CML patients in advanced 
phase CML and in “interferon failing” CP.  
We included information on all newly diagnosed CML patients (n=3173; 1796 males and 1377 
females; median age 62 years), reported to the Swedish Cancer Registry140 from 1973 to 2008 
using the International Classification of Diseases Version 7 (ICD 7). The diagnosis was coded 
as 2051. Patients in all phases of CML were included. The exact proportion of patients 
diagnosed in the advanced phases is known only for period the 2002-2008: 4% in AP and 3% in 
BP. The Swedish CML Registry, to which more detailed information about disease charac-
teristics is reported, was established in 2002,53. Information from the Swedish Cancer 
Registry140 included date of birth, gender, date of diagnosis, region, and hospital where the 
diagnosis was made. All patients were observed from the date of diagnosis until death, 
emigration, or end of follow-up (December 31, 2009). We excluded individuals who were 
diagnosed incidentally at autopsy. The choice to include patients from 1973 was based on the 
fact that by then, the Swedish Cancer Registry, established 1958, had reached a high rate of 
coverage.168,169 Patients with a preceding cancer diagnosis, including those with a hematological 
malignancy, were included. Date of death was obtained from Cause of Death Registry.139 
Information of the use of upfront imatinib was collected from the Swedish CML registry. 
Information on the number of SCTs performed in CML patients during this time period was 
obtained from the registry of the European Group for Blood and Marrow Transplantation 
(EBMT), established in 1974.  
 
5.1.1  Statistical methods 
Relative survival ratios (RSR) were computed as measures of CML survival.170,171 The 
important advantage of using RS is that it does not rely on the accurate classification of cause of 
death. Instead, in this project it provides a measure of total excess mortality associated with the 
diagnosis of CML, irrespective of whether the excess mortality was a direct or indirect result of 
the cancer (here CML). As such, the RSR allows capturing the excess mortality resulting from, 
e.g. infection or second primary malignancies, which is not possible when using cause-specific 
survival. The RSR is defined as observed survival in the patient group (where all deaths are 
considered as events) divided by the expected survival of a comparable group from the general 
population, which is assumed to be free from the cancer in question. One, 5 and 10 year RSRs 
can be interpreted as the proportion of patients with CML who survived the malignancy at 1, 5 
and 10 years, respectively. Expected survival was estimated using the Ederer II method172 from 
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Swedish population life tables stratified by age, sex, and calendar period. One, 5, and 10 year 
RSRs were calculated for patients diagnosed during five calendar periods and five age 
categories. Poisson regression was used to model excess mortality173 to estimate the effects of 
the factor described, while controlling for potential confounding factors. Parameter estimates 
from this model are interpreted as excess mortality rate ratios (EMRRs). An EMRR of e.g. 1.5 
for men/women indicates that men experience a 50% higher excess mortality rate (difference 
between observed and expected mortality) than women. All calculations were performed using 
Stata 11 (StataCorp, College Station, TX). 
 
5.2  RESULTS AND DISCUSSION 
Using data from the population-based Swedish Cancer Registry and population life tables, we 
estimated RS for all patients diagnosed with CML between 1973-2008. Patients were 
categorized into five age groups and five calendar periods (<50, 50-59, 60-69, 70-79, >79 years; 
and 1973-1979, 1980-1986, 1987-1993, 1994-2000, 2001-2008.) 
Relative survival improved with each calendar period, with the greatest improvement between 
1994-2000 and 2001-2008. Five-year cumulative relative survival ratios (95% Cls) were 0.21 
(0.17-0.24) for patients diagnosed 1973-1979, 0.23 (0.20-0.27), 0.37 (0.33-0.41) 0.54 (0.50-
0.58) 1994-2000, and 0.80 (0.75-0.83) for 1980-1986, 1987-1993, 1994-2000 and 2001-2008, 
respectively. This improvement was confined to patients younger than 79 years of age. Five-
year RSRs for patients diagnosed from 2001 to 2008 were 0.91 (95% CI, 0.85 to 0.94) and 0.25 
(95% CI, 0.10-0.47) for patients younger than 50 and older than 79 years, respectively. Men had 
inferior outcome. Upfront overall use of imatinib increased from 40% (2002) to 84% (2006). 
Only 18% of patients older than 80 years of age received imatinib as first-line therapy. 
Throughout all calendar periods age was a strong predictor of survival, with superior survival 
in the youngest patients. In analyses including age and period of diagnosis, RS clearly 
improved with calendar period in all age groups, but was most pronounced in patients 
younger than 79 years of age, particularly those 70 to 79 years of age. The use of imatinib as 
first line treatment was confirmed by data from the national CML registry. Imatinib was used 
in 40% of the newly diagnosed CML patients in 2002, in 78% 2004, and in 90% in 2007. This 
large population-based study reveals a major improvement in outcome of patients with CML up 
to 79 years of age diagnosed from 2001 to 2008, mainly caused by an increasing use of 
imatinib. The elderly patients still had a poor outcome, partly because of a limited use of 
imatinib. However, according to a later report from the Swedish CML registry53, the primary 
use of imatinib (or other TKI) in patients >80 years of age, diagnosed 2007 - 2010, has 
increased to 72%, showing an attitude change in the approach to the treatment of CML in the 
elderly, in favor of more active treatment. 
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Figure 7. Cumulative relative survival by age (years) and period of diagnosis. 
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6  HEALTH ECONOMIC ASPECTS OF CML TREATMENT (IV) 
6.1  PATIENTS AND METHODS 
Medical advances have improved the outcome for patients with CML, especially during the 
most recent decade. The tyrosine kinase inhibitor imatinib was introduced in the treatment of 
CML 2000-2001 and has been a breakthrough in treatment of CML. Imatinib allows a faster, 
deeper and more pronounced reduction of BCR-ABL transcript levels than previously available 
drug therapy. This is associated with a lower rate of progression and an improvement of 
survival130 leading to an increased prevalence. One disadvantage with imatinib and other TKIs 
is that they are costly to the society. We wanted to compare the costs of different decades and to 
relate the costs to the expected improved survival. Using the unique real world national data 
from CML patients diagnosed in Sweden from 1973 to 2008, (n=1778) we evaluated the 
incremental cost-effectiveness ratio (ICER) between periods associated with broad 
implementation of imatinib, (Glivec®), IFN and allogeneic SCT, and symptomatic treatment, 
respectively. 
6.1.1  Statistical methods 
A lifetime cohort cost-effectiveness model with three age cohorts (<50; 50-69; and 70+ years) 
diagnosed during three calendar periods (I: 1973−1979; II: 1991−1997; III: 2002−2008) was 
developed. The number of patients diagnosed in each calendar period was I: 609, II: 576, III: 
593. The three periods were selected in order to capture broad implementation of three different 
treatment therapies prevailing at the respective time period, namely; I. Busulphan II. Allogeneic 
SCT or a combination of IFN and hydroxyurea and III. Imatinib. The stratification of data into 
age cohorts reflected the fact that treatment decisions were made partly with respect to age, 
where patients eligible to allogeneic SCT were typically younger than 50 years. The model 
allowed separate distributions of therapies (type, resource use) and outcome (survival, quality of 
life) for each age cohort and period (I-III) 
We compared the quality adjusted life years (QALYs) and lifetime costs for an average person 
if treated for CML with therapies as provided in each of the three periods. The value of 
continued medical advances was compared by calculating the incremental cost-effectiveness 
ratio (ICER) per QALY gained for each period compared to the previous period. For example, 
the ICER of period III versus period II was: 
 !"#$ = !"#$%"&$  !"#$#  (!"#$%&  !!!)−   !"#$%"&$  !"#$#  (!"#$%&  !!)!"#$%  (!"#$%&  !!!)− !"#$%    (!"#$%&  !!)  
 
We applied a health-sector perspective and a societal perspective. All prices reflected Swedish 
prices in year 2011 and were expressed in pound sterling (1GBP=10.4 SEK). Costs and health 
gains were discounted by 3% following Swedish health economic guidelines.174 Survival data 
from all patients included was obtained from the national wide Swedish Cancer Registry and 
Cause of Death Registry. All patients were followed from date of diagnosis until death, 
emigration or end of follow up, December 31st 2009. Health-care costs for each therapy were 
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estimated from Swedish clinical practice, following the Swedish guidelines. We included 
resources as blood tests, bone marrow tests, chromosomal analyses, qRT-PCR, allogeneic SCT, 
special visits, inpatient days, and costs for the drugs (busulphan, IFN, hydroxyurea and 
imatinib) and finally care related to BP. According to Swedish health economic guidelines, 
economic evaluations should also consider the effect of net consumption (total consumption 
minus total production) from increased survival.174 The health-sector perspective only includes 
health care costs while the societal perspective includes both health care costs and net 
consumption. 
A recently published study by Mahon et al82 has suggested that imatinib may be successfully 
discontinued in a subpopulation of patients with excellent treatment response showing no PCR-
detectable minimal residual disease. Furthermore, since the imatinib (Glivec®) patent in 
Sweden will expire in 2016, opening the market for biosimilars, it is estimated that the overall 
drug costs for CML may then be reduced by approximately 30-80%. To compute these future 
perspective we also analysed two different, possible upcoming scenarios A) Discontinuation of 
imatinib and B) Price reduction of imatinib. 
 
6.2  RESULTS AND DISCUSSION 
We observed substantial health gains over time, paralleled by increased treatment costs. The 
mean survival was 2.9, 9.2 and 18.5 years during periods I-III, respectively. The resulting ICER 
was £45 700 per QALY gained comparing periods III and II using a societal perspective and a 
similar result adopting the limited health-sector perspective. In a separate analysis by age 
groups showed lower ICERs for individuals <50 years at diagnosis: £38 500 for the societal 
perspective and £47 700 per QALY gained for the health-sector perspective. Since the 
prevalence of CML patients is increasing and assuming that 75% of each incident cohort was to 
receive imatinib at current prices, the imatinib budget would need to double by 2050. A future 
potential discontinuation of imatinib for selected excellent responders would reduce the ICER 
per QALY gained. Reduced drug cost of imatinib linked to the patent expiry of Glivec will 
probably have a greater impact of ICER per QALY. An estimated price reduction of 80% 
(global competition) or 30% (expected change for biological drugs) would be associated with 
an ICER of £20 000 and £36 000, respectively, per QALY gained. 
Our study focused on imatinib treated patients. However, imatinib has for the last 5 years 
gradually been replaced by 2nd generation TKIs for many patients, partly as second line 
treatment because of intolerance or resistance to imatinib and partly as first line treatment, as 
trials have shown that these drugs provide a faster and deeper molecular response. This change 
in prescribing pattern is not taken into account in this analysis.  
Nevertheless these health economic analyses reveal a dramatically prolonged survival for CML 
patients during four decades of development, paralleled by incremental cost-effectiveness ratios 
at levels generally accepted by some, but not all Western national health authorities. 
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Figure 8. Prevalence of CML per 100 000 inhabitants year 1980-2050 and the predicted drug costs for 
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7  SUMMARY AND CONCLUSIONS  
I 
Our landmark data indicate that ES-FISH may be used already after 3 months of imatinib 
treatment, to identify a patient cohort with inferior long-term EFS. From our data FISH appears 
to be more sensitive than PCR. The observation that PCR did not give the predictive values as 
other groups have found, may be explained by the fact that we did not use the IS. Of patients 
with FISH levels < 10% after 3 months of imatinib treatment 95% achieved CCyR within 12 
months and 100% had an event free survival at 48 months. FISH can effectively be used in the 
early assessment of remaining Ph-positive cells to identify patients at risk for a long-term non-
optimal response to imatinib. 
 
II 
Neutrophils from CML patients showed an increased expression and activity of LTC4S. In vivo 
treatment with imatinib normalized this pattern. This normalization occurred faster than the 
cytogenetic response. The observation indicates that expression and activity of LTC4S may be a 
down-stream step in the signal transduction events initiated by the Bcr-Abl tyrosine kinase. It is 
possible that an early evaluation of LTC4S expression during imatinib treatment could be a 
more rapid way of assessing treatment response than by conventional methods identifying 
BCR-ABL expression (through CBA, FISH or qRT-PCR). 
 
III 
Survival in CML has improved significantly since the 1970s. In all calendar periods, age was a 
strong predictor of survival, with superior survival for the youngest patients.  
In analyses including age and period of diagnosis, RS improved with calendar period in all age 
groups, but most pronounced in patients younger than 79 years of age, particular those 70-79 
years of age. We observed a moderate but statistically significant better survival for women, 
when adjusted for age and calendar period. 
The improvement of survival started 1987-1993. Major contributing factor to the improvement 
observed were an increasing number of allogeneic SCT, the introduction of IFN, better 
supportive care and more aggressive treatment in both chronic and accelerated phases.  
Survival among all age groups was greatest in the last calendar period, but patients older than 
79 still do poorly. The Swedish CML registry data shows that patients diagnosed 2002-2008, 
70-79 years old received TKIs in 66% and patients >80 years in only 18%. This observation has 
resulted in an increased use of the TKIs in elderly patients. A recent report from the CML 
registry, reveals that the primary use of imatinib in patients >80 years diagnosed 2007-2010 has 




Substantial health gains were noted over the three calendar periods (I: 1973-1979, II: 1991-
1997, and III: 2002-2008), paralleled by increased treatment costs. The mean survival was 2.9, 
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9.2 and 18.5 years during periods I-III. The health economic analyses reveal dramatically 
prolonged survival for CML patients during the four decades, with incremental cost-
effectiveness ratios at levels generally accepted by Swedish and some but not all Western 
national health authorities. 
  11 
8  ACKNOWLEDGEMENTS 
To my own surprise I finished this thesis, but it would not have been possible without help and 
support of many important persons around me. In particular I wish to thank: 
 
Leif Stenke, my main supervisor, for sharing your enormous knowledge of CML with me. For 
never giving up on me when I was grumpy… you are such an encouraging person. For evening- 
and weekend-meetings, working on this project. For all the fun we have and together with 
others, making music together. 
Robert Hast, my co-supervisor and former main supervisor. You hooked me up on hematology 
and introduced me into the world of research and learned me everything worth knowing about 
being a hematologist. You have been such a great guide. 
Magnus Björkholm my co-supervisor, for sharing your vast knowledge, for support, 
encouragement and for guiding me in this thesis fight. 
Ingrid Arvidsson for teaching me about FISH and for being a great co-author and friend. 
Martin Höglund, Johan Richter, Ola Landgren, Malin Hultcrantz, Janne Sjöberg, 
Susanne Widell, Maria Kumlin, Jan Åke Lindgren, Gisela Barbany, Susanne Tornhamre 
and especially Cecilia Roos, Adam Lundqvist and Katarina Steen Carlsson, my co-authors 
for great discussions and great collaboration. 
Paul Dickman, Sandra Eloranta, Therese Andersson my co-authors, for invaluable statistical 
discussions and work.  
Per Ljungman and Viktoria Hjalmar for providing an environment where it is possible to 
combine research and clinical work. 
Ana Petrescu who conjured with the schedule, letting me do my research when I needed and 
for all the laughs (especially when talking about everyday experiences).  
Pelle Bernell my clinical tutor, for all encouragement and trusts you have been given me over 
the years and for great friendship. 
Åsa Derolf, my co-author, for your practical advice, how to finish this project. 
Sigurdur Yngvi Kristinsson, my co-author for guiding me in to the world of RSRs. 
Olga Stromberg, my roommate, for being such a good example of being a doctor and a great 
friend. You are bringing joy! 
All my colleagues and friends at Division of Hematology, for great collaboration, genuine 
friendship, fruitful discussions and social activities. It is such a privilege working together with 
dedicated people. 
Harriet Ryblom, the perfect study nurse, for great collaboration and for reminding me of all 
kind of stuff. 
Ninni Petersen for all super-secretarial help, always being one step ahead! 
Members of the Swedish CML Group and the Nordic CML Study Group, for all exciting 
collaboration in clinical research. 
All CML patients, for participating in our studies and thus contribute to increase the 
knowledge of CML. 
My friends, for just being there in good and bad times 
and finally to  
My warm-hearted beloved family, for everything. This thesis is dedicated to you. 
  12 
9  REFERENCES 
 1. Degos L: John Hughes Bennett, Rudolph Virchow... and Alfred Donne: the first 
description of leukemia. The hematology journal : the official journal of the European 
Haematology Association / EHA 2:1, 2001 
 2. Seufert W, Seufert WD: The recognition of leukemia as a systemic disease. Journal of 
the history of medicine and allied sciences 37:34-50, 1982 
 3. E. N: Uber myelogene leukemia. Berliner Klinische Wochenschreibe 15:69-72, 1878 
 4. Nowell PC, Hungerford DA: Chromosome studies on normal and leukemic human 
leukocytes. Journal of the National Cancer Institute 25:85-109, 1960 
 5. Rowley JD: Letter: A new consistent chromosomal abnormality in chronic 
myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. 
Nature 243:290-3, 1973 
 6. Bartram CR, de Klein A, Hagemeijer A, et al: Translocation of c-ab1 oncogene 
correlates with the presence of a Philadelphia chromosome in chronic myelocytic 
leukaemia. Nature 306:277-80, 1983 
 7. Groffen J, Stephenson JR, Heisterkamp N, et al: Philadelphia chromosomal 
breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93-
9, 1984 
 8. Shtivelman E, Lifshitz B, Gale RP, et al: Fused transcript of abl and bcr genes in 
chronic myelogenous leukaemia. Nature 315:550-4, 1985 
 9. Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia 
in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824-30, 
1990 
 10. Wedelin C, Bjorkholm M, Mellstedt H, et al: Clinical findings and prognostic factors 
in chronic myeloid leukemias. Acta medica Scandinavica 220:255-60, 1986 
 11. Goldman JM, Melo JV: Chronic myeloid leukemia--advances in biology and new 
approaches to treatment. The New England journal of medicine 349:1451-64, 2003 
 12. Hehlmann R, Berger U, Pfirrmann M, et al: Randomized comparison of interferon 
alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia 
(CML-study II): prolongation of survival by the combination of interferon alpha and 
hydroxyurea. Leukemia : official journal of the Leukemia Society of America, 
Leukemia Research Fund, U.K 17:1529-37, 2003 
 13. Baccarani M, Russo D, Rosti G, et al: Interferon-alfa for chronic myeloid leukemia. 
Seminars in hematology 40:22-33, 2003 
 14. Garcia-Manero G, Faderl S, O'Brien S, et al: Chronic myelogenous leukemia: a review 
and update of therapeutic strategies. Cancer 98:437-57, 2003 
 15. Olsson-Stromberg U, Simonsson B, Ahlgren T, et al: Comparison of busulphan, 
hydroxyurea and allogeneic bone marrow transplantation (BMT) in chronic myeloid 
leukaemia: BMT prolongs survival. The hematology journal : the official journal of the 
European Haematology Association / EHA 5:462-6, 2004 
 16. Simonsson B, Oberg G, Bjoreman M, et al: Intensive treatment in order to minimize 
the Ph-positive clone in CML. Danish-Swedish CML Group. Bone marrow 
transplantation 17 Suppl 3:S63-4, 1996 
  13 
 17. Axdorph U, Stenke L, Grimfors G, et al: Intensive chemotherapy in patients with 
chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from 
the Swedish CML Group. British journal of haematology 118:1048-54, 2002 
 18. Takahashi N, Miura I, Saitoh K, et al: Lineage involvement of stem cells bearing the 
philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown 
by a combination of fluorescence-activated cell sorting and fluorescence in situ 
hybridization. Blood 92:4758-63, 1998 
 19. Coulombel L, Kalousek DK, Eaves CJ, et al: Long-term marrow culture reveals 
chromosomally normal hematopoietic progenitor cells in patients with Philadelphia 
chromosome-positive chronic myelogenous leukemia. The New England journal of 
medicine 308:1493-8, 1983 
 20. Petzer AL, Eaves CJ, Lansdorp PM, et al: Characterization of primitive subpopulations 
of normal and leukemic cells present in the blood of patients with newly diagnosed as 
well as established chronic myeloid leukemia. Blood 88:2162-71, 1996 
 21. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health 
Organization (WHO) classification of myeloid neoplasms and acute leukemia: 
rationale and important changes. Blood 114:937-51, 2009 
 22. Jaffe ES, Harris NL, Diebold J, et al: World Health Organization classification of 
neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. 
American journal of clinical pathology 111:S8-12, 1999 
 23. Akel S, Kolialexi A, Mavrou A, et al: Evaluation at single cell level of residual 
Philadelphia negative hemopoietic stem cells in chronic phase CML patients. Cancer 
genetics and cytogenetics 122:93-100, 2000 
 24. Akel S, Kolialexi A, Mavrou A, et al: Efficiency of interphase fluorescence in situ 
hybridization for BCR/ABL on peripheral blood smears for monitoring of CML 
patients: a comparison with bone marrow findings. Clinical and laboratory 
haematology 24:361-7, 2002 
 25. Landstrom AP, Ketterling RP, Knudson RA, et al: Utility of peripheral blood dual 
color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess 
cytogenetic remission status in chronic myeloid leukemia. Leukemia & lymphoma 
47:2055-61, 2006 
 26. Le Gouill S, Talmant P, Milpied N, et al: Fluorescence in situ hybridization on 
peripheral-blood specimens is a reliable method to evaluate cytogenetic response in 
chronic myeloid leukemia. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 18:1533-8, 2000 
 27. Duba HC, Hilbe W, Mehringer A, et al: Hypermetaphase and interphase fluorescence 
in situ hybridisation for monitoring of remission status in Philadelphia chromosome 
positive chronic myeloid leukaemia. International journal of oncology 17:1245-9, 2000 
 28. Schoch C, Schnittger S, Bursch S, et al: Comparison of chromosome banding analysis, 
interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis 
and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia : 
official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 
16:53-9, 2002 
 29. Testoni N, Marzocchi G, Luatti S, et al: Chronic myeloid leukemia: a prospective 
comparison of interphase fluorescence in situ hybridization and chromosome banding 
analysis for the definition of complete cytogenetic response: a study of the GIMEMA 
CML WP. Blood 114:4939-43, 2009 
  14 
 30. Cross NC: Minimal residual disease in chronic myeloid leukaemia. Hematology and 
cell therapy 40:224-8, 1998 
 31. Hughes T, Deininger M, Hochhaus A, et al: Monitoring CML patients responding to 
treatment with tyrosine kinase inhibitors: review and recommendations for 
harmonizing current methodology for detecting BCR-ABL transcripts and kinase 
domain mutations and for expressing results. Blood 108:28-37, 2006 
 32. Hughes TP, Kaeda J, Branford S, et al: Frequency of major molecular responses to 
imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid 
leukemia. The New England journal of medicine 349:1423-32, 2003 
 33. Branford S, Fletcher L, Cross NC, et al: Desirable performance characteristics for 
BCR-ABL measurement on an international reporting scale to allow consistent 
interpretation of individual patient response and comparison of response rates between 
clinical trials. Blood 112:3330-8, 2008 
 34. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses 
to imatinib mesylate in chronic myelogenous leukemia. The New England journal of 
medicine 346:645-52, 2002 
 35. Kantarjian HM, Talpaz M, Giles F, et al: New insights into the pathophysiology of 
chronic myeloid leukemia and imatinib resistance. Annals of internal medicine 
145:913-23, 2006 
 36. Chase A, Huntly BJ, Cross NC: Cytogenetics of chronic myeloid leukaemia. Best 
practice & research. Clinical haematology 14:553-71, 2001 
 37. Baccarani M, Saglio G, Goldman J, et al: Evolving concepts in the management of 
chronic myeloid leukemia: recommendations from an expert panel on behalf of the 
European LeukemiaNet. Blood 108:1809-20, 2006 
 38. Network NCC, http://www.ncc.org 
 39. Saikia T, Advani S, Dasgupta A, et al: Characterisation of blast cells during blastic 
phase of chronic myeloid leukaemia by immunophenotyping--experience in 60 
patients. Leukemia research 12:499-506, 1988 
 40. Khalidi HS, Brynes RK, Medeiros LJ, et al: The immunophenotype of blast 
transformation of chronic myelogenous leukemia: a high frequency of mixed lineage 
phenotype in "lymphoid" blasts and A comparison of morphologic, 
immunophenotypic, and molecular findings. Modern pathology : an official journal of 
the United States and Canadian Academy of Pathology, Inc 11:1211-21, 1998 
 41. Nair C, Chopra H, Shinde S, et al: Immunophenotype and ultrastructural studies in 
blast crisis of chronic myeloid leukemia. Leukemia & lymphoma 19:309-13, 1995 
 42. Derderian PM, Kantarjian HM, Talpaz M, et al: Chronic myelogenous leukemia in the 
lymphoid blastic phase: characteristics, treatment response, and prognosis. The 
American journal of medicine 94:69-74, 1993 
 43. O'Brien S, Abboud CN, Akhtari M, et al: Chronic myelogenous leukemia. Journal of 
the National Comprehensive Cancer Network : JNCCN 10:64-110, 2012 
 44. Ilaria RL, Jr.: Pathobiology of lymphoid and myeloid blast crisis and management 
issues. Hematology / the Education Program of the American Society of Hematology. 
American Society of Hematology. Education Program:188-94, 2005 
 45. Sokal JE, Cox EB, Baccarani M, et al: Prognostic discrimination in "good-risk" 
chronic granulocytic leukemia. Blood 63:789-99, 1984 
  15 
 46. Hochhaus A, O'Brien SG, Guilhot F, et al: Six-year follow-up of patients receiving 
imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia : official 
journal of the Leukemia Society of America, Leukemia Research Fund, U.K 23:1054-
61, 2009 
 47. Hasford J, Pfirrmann M, Hehlmann R, et al: A new prognostic score for survival of 
patients with chronic myeloid leukemia treated with interferon alfa. Writing 
Committee for the Collaborative CML Prognostic Factors Project Group. Journal of 
the National Cancer Institute 90:850-8, 1998 
 48. Hasford J, Baccarani M, Hoffmann V, et al: Predicting complete cytogenetic response 
and subsequent progression-free survival in 2060 patients with CML on imatinib 
treatment: the EUTOS score. Blood 118:686-92, 2011 
 49. Baccarani M, Cortes J, Pane F, et al: Chronic myeloid leukemia: an update of concepts 
and management recommendations of European LeukemiaNet. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 27:6041-51, 
2009 
 50. Young JL, Jr., Percy CL, Asire AJ, et al: Cancer incidence and mortality in the United 
States, 1973-77. National Cancer Institute monograph:1-187, 1981 
 51. Faderl S, Talpaz M, Estrov Z, et al: Chronic myelogenous leukemia: biology and 
therapy. Annals of internal medicine 131:207-19, 1999 
 52. Cancercentrum HMR: Redovisning av material 2002-2010, Blodcancerregistret, 
Nationellt register för Kronisk Myeloisk Leukemi (KML).2011 
 53. Höglund: Nationellt Register för kronisk Myeloisk Leukemi Rapport nr 5, 
http//http://www.roc.se/hematologi/KML, 2011 
 54. Rohrbacher M, Hasford J: Epidemiology of chronic myeloid leukaemia (CML). Best 
practice & research. Clinical haematology 22:295-302, 2009 
 55. Hehlmann R, Hochhaus A, Baccarani M: Chronic myeloid leukaemia. Lancet 
370:342-50, 2007 
 56. Deininger MW, Bose S, Gora-Tybor J, et al: Selective induction of leukemia-
associated fusion genes by high-dose ionizing radiation. Cancer research 58:421-5, 
1998 
 57. Moloney WC: Radiogenic leukemia revisited. Blood 70:905-8, 1987 
 58. Tanaka K, Takechi M, Hong J, et al: 9;22 translocation and bcr rearrangements in 
chronic myelocytic leukemia patients among atomic bomb survivors. Journal of 
radiation research 30:352-8, 1989 
 59. Corso A, Lazzarino M, Morra E, et al: Chronic myelogenous leukemia and exposure to 
ionizing radiation--a retrospective study of 443 patients. Annals of hematology 70:79-
82, 1995 
 60. UNSCEAR: Health effects due to radiation from Chernobyl accident., in radiation 
UUNSCoEoA (ed), 2011 
 61. Kozubek S, Lukasova E, Ryznar L, et al: Distribution of ABL and BCR genes in cell 
nuclei of normal and irradiated lymphocytes. Blood 89:4537-45, 1997 
 62. Neves H, Ramos C, da Silva MG, et al: The nuclear topography of ABL, BCR, PML, 
and RARalpha genes: evidence for gene proximity in specific phases of the cell cycle 
and stages of hematopoietic differentiation. Blood 93:1197-207, 1999 
  16 
 63. Saglio G, Storlazzi CT, Giugliano E, et al: A 76-kb duplicon maps close to the BCR 
gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in 
the genesis of the Philadelphia chromosome translocation. Proceedings of the National 
Academy of Sciences of the United States of America 99:9882-7, 2002 
 64. Bose S, Deininger M, Gora-Tybor J, et al: The presence of typical and atypical BCR-
ABL fusion genes in leukocytes of normal individuals: biologic significance and 
implications for the assessment of minimal residual disease. Blood 92:3362-7, 1998 
 65. Biernaux C, Sels A, Huez G, et al: Very low level of major BCR-ABL expression in 
blood of some healthy individuals. Bone marrow transplantation 17 Suppl 3:S45-7, 
1996 
 66. Posthuma EF, Falkenburg JH, Apperley JF, et al: HLA-B8 and HLA-A3 coexpressed 
with HLA-B8 are associated with a reduced risk of the development of chronic 
myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 
93:3863-5, 1999 
 67. Deininger MW, Goldman JM, Melo JV: The molecular biology of chronic myeloid 
leukemia. Blood 96:3343-56, 2000 
 68. Fialkow PJ, Jacobson RJ, Papayannopoulou T: Chronic myelocytic leukemia: clonal 
origin in a stem cell common to the granulocyte, erythrocyte, platelet and 
monocyte/macrophage. The American journal of medicine 63:125-30, 1977 
 69. Heisterkamp N, Stam K, Groffen J, et al: Structural organization of the bcr gene and its 
role in the Ph' translocation. Nature 315:758-61, 1985 
 70. Sawyers CL, McLaughlin J, Goga A, et al: The nuclear tyrosine kinase c-Abl 
negatively regulates cell growth. Cell 77:121-31, 1994 
 71. Apperley JF: Part I: mechanisms of resistance to imatinib in chronic myeloid 
leukaemia. The lancet oncology 8:1018-29, 2007 
 72. Cohen GB, Ren R, Baltimore D: Modular binding domains in signal transduction 
proteins. Cell 80:237-48, 1995 
 73. ABL1 c-abl oncogene 1, non-receptor tyrosine kinase [homo sapiens], NCBI 2013 
 74. Sawyers CL: Chronic myeloid leukemia. The New England journal of medicine 
340:1330-40, 1999 
 75. Pasternak G, Hochhaus A, Schultheis B, et al: Chronic myelogenous leukemia: 
molecular and cellular aspects. Journal of cancer research and clinical oncology 
124:643-60, 1998 
 76. Johansson B, Fioretos T, Mitelman F: Cytogenetic and molecular genetic evolution of 
chronic myeloid leukemia. Acta haematologica 107:76-94, 2002 
 77. O'Brien SG, Guilhot F, Larson RA, et al: Imatinib compared with interferon and low-
dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. The 
New England journal of medicine 348:994-1004, 2003 
 78. Allan NC, Richards SM, Shepherd PC: UK Medical Research Council randomised, 
multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved 
survival irrespective of cytogenetic response. The UK Medical Research Council's 
Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345:1392-7, 1995 
 79. Deininger M OBS, Guilhot F, et al.: International randomized study of interferon vs 
STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or 
  17 
event in chronic phase (CML-CP) treated with imatinib [ Abstract]. Blood 114:1126, 
2009 
 80. Kantarjian H, O'Brien S, Jabbour E, et al: Improved survival in chronic myeloid 
leukemia since the introduction of imatinib therapy: a single-institution historical 
experience. Blood 119:1981-7, 2012 
 81. Rousselot P, Huguet F, Rea D, et al: Imatinib mesylate discontinuation in patients with 
chronic myelogenous leukemia in complete molecular remission for more than 2 years. 
Blood 109:58-60, 2007 
 82. Mahon FX, Rea D, Guilhot J, et al: Discontinuation of imatinib in patients with 
chronic myeloid leukaemia who have maintained complete molecular remission for at 
least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. The lancet 
oncology 11:1029-35, 2010 
 83. Schindler T, Bornmann W, Pellicena P, et al: Structural mechanism for STI-571 
inhibition of abelson tyrosine kinase. Science 289:1938-42, 2000 
 84. Buchdunger E, Zimmermann J, Mett H, et al: Inhibition of the Abl protein-tyrosine 
kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer research 
56:100-4, 1996 
 85. Buchdunger E, Cioffi CL, Law N, et al: Abl protein-tyrosine kinase inhibitor STI571 
inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth 
factor receptors. The Journal of pharmacology and experimental therapeutics 295:139-
45, 2000 
 86. Druker BJ, Lydon NB: Lessons learned from the development of an abl tyrosine kinase 
inhibitor for chronic myelogenous leukemia. The Journal of clinical investigation 
105:3-7, 2000 
 87. Deininger MW, O'Brien SG, Ford JM, et al: Practical management of patients with 
chronic myeloid leukemia receiving imatinib. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 21:1637-47, 2003 
 88. Mauro MJ, Deininger MW: Management of drug toxicities in chronic myeloid 
leukaemia. Best practice & research. Clinical haematology 22:409-29, 2009 
 89. Marin D, Marktel S, Bua M, et al: The use of imatinib (STI571) in chronic myelod 
leukemia: some practical considerations. Haematologica 87:979-88, 2002 
 90. Bumming P, Andersson J, Meis-Kindblom JM, et al: Neoadjuvant, adjuvant and 
palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-
based study of 17 patients. British journal of cancer 89:460-4, 2003 
 91. Dematteo RP, Ballman KV, Antonescu CR, et al: Adjuvant imatinib mesylate after 
resection of localised, primary gastrointestinal stromal tumour: a randomised, double-
blind, placebo-controlled trial. Lancet 373:1097-104, 2009 
 92. Jonsson S, Lewerin C, Jacobsson S, et al: [Hypereosinophilic syndrome--difficult-to-
catch diagnosis. Targeted molecular diagnostics and treatment now possible thanks to 
gene discovery]. Lakartidningen 103:2556-9, 2006 
 93. Bain BJ: Eosinophilic leukemia and idiopathic hypereosinophilic syndrome are 
mutually exclusive diagnoses. Blood 104:3836; author reply 3836-7, 2004 
 94. Coutre S, Gotlib J: Targeted treatment of hypereosinophilic syndromes and chronic 
eosinophilic leukemias with imatinib mesylate. Seminars in cancer biology 14:23-31, 
2004 
  18 
 95. Pardanani A, Tefferi A: Imatinib therapy for hypereosinophilic syndrome and 
eosinophilia-associated myeloproliferative disorders. Leukemia research 28 Suppl 
1:S47-52, 2004 
 96. Abrams TA, Schuetze SM: Targeted therapy for dermatofibrosarcoma protuberans. 
Current oncology reports 8:291-6, 2006 
 97. Towatari M, Yanada M, Usui N, et al: Combination of intensive chemotherapy and 
imatinib can rapidly induce high-quality complete remission for a majority of patients 
with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 
104:3507-12, 2004 
 98. Thomas DA, Faderl S, Cortes J, et al: Treatment of Philadelphia chromosome-positive 
acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 
103:4396-407, 2004 
 99. Ottmann OG, Pfeifer H: Management of Philadelphia chromosome-positive acute 
lymphoblastic leukemia (Ph+ ALL). Hematology / the Education Program of the 
American Society of Hematology. American Society of Hematology. Education 
Program:371-81, 2009 
 100. Soupir CP, Vergilio JA, Dal Cin P, et al: Philadelphia chromosome-positive acute 
myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct 
from chronic myeloid leukemia in myeloid blast crisis. American journal of clinical 
pathology 127:642-50, 2007 
 101. Hochhaus A: Molecular response and BCR-ABL reductions in patients with newly 
diagnosed chronic myeloid leukemia in chronic  phase receiving dasatinib versus 
imatinib: Dasision 3-Year Follow-up. Atlanta USA, ASH meeting 2012, 2012  
 102. Porkka K, Khoury HJ, Paquette RL, et al: Dasatinib 100 mg once daily minimizes the 
occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic 
phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 
116:377-86, 2010 
 103. Apperley JF, Cortes JE, Kim DW, et al: Dasatinib in the treatment of chronic myeloid 
leukemia in accelerated phase after imatinib failure: the START a trial. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 
27:3472-9, 2009 
 104. Shah NP, Kim DW, Kantarjian H, et al: Potent, transient inhibition of BCR-ABL with 
dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high 
transformation-free survival rates in chronic phase chronic myeloid leukemia patients 
with resistance, suboptimal response or intolerance to imatinib. Haematologica 95:232-
40, 2010 
 105. Cortes J, Rousselot P, Kim DW, et al: Dasatinib induces complete hematologic and 
cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid 
leukemia in blast crisis. Blood 109:3207-13, 2007 
 106. Hochhaus A, Kantarjian HM, Baccarani M, et al: Dasatinib induces notable 
hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia 
after failure of imatinib therapy. Blood 109:2303-9, 2007 
 107. Mustjoki S, Auvinen K, Kreutzman A, et al: Rapid mobilization of cytotoxic 
lymphocytes induced by dasatinib therapy. Leukemia : official journal of the Leukemia 
Society of America, Leukemia Research Fund, U.K, 2012 
  19 
 108. de Lavallade H, Punnialingam S, Milojkovic D, et al: Pleural effusions in patients with 
chronic myeloid leukaemia treated with dasatinib may have an immune-mediated 
pathogenesis. British journal of haematology 141:745-7, 2008 
 109. Saglio G, Kim DW, Issaragrisil S, et al: Nilotinib versus imatinib for newly diagnosed 
chronic myeloid leukemia. The New England journal of medicine 362:2251-9, 2010 
 110. Larson RA, Hochhaus A, Hughes TP, et al: Nilotinib vs imatinib in patients with 
newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in 
chronic phase: ENESTnd 3-year follow-up. Leukemia : official journal of the 
Leukemia Society of America, Leukemia Research Fund, U.K 26:2302, 2012 
 111. Kantarjian H: Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs 
Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive 
(Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Atlanta, 2012  
 112. Deremer DL, Ustun C, Natarajan K: Nilotinib: a second-generation tyrosine kinase 
inhibitor for the treatment of chronic myelogenous leukemia. Clinical therapeutics 
30:1956-75, 2008 
 113. Hantschel O, Rix U, Superti-Furga G: Target spectrum of the BCR-ABL inhibitors 
imatinib, nilotinib and dasatinib. Leukemia & lymphoma 49:615-9, 2008 
 114. Rix U, Hantschel O, Durnberger G, et al: Chemical proteomic profiles of the BCR-
ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase 
targets. Blood 110:4055-63, 2007 
 115. Palandri F, Castagnetti F, Testoni N, et al: Chronic myeloid leukemia in blast crisis 
treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. 
Haematologica 93:1792-6, 2008 
 116. Ljungman P, Bregni M, Brune M, et al: Allogeneic and autologous transplantation for 
haematological diseases, solid tumours and immune disorders: current practice in 
Europe 2009. Bone marrow transplantation 45:219-34, 2010 
 117. Copelan EA, Crilley PA, Szer J, et al: Late mortality and relapse following BuCy2 and 
HLA-identical sibling marrow transplantation for chronic myelogenous leukemia. 
Biology of blood and marrow transplantation : journal of the American Society for 
Blood and Marrow Transplantation 15:851-5, 2009 
 118. Kiss TL, Abdolell M, Jamal N, et al: Long-term medical outcomes and quality-of-life 
assessment of patients with chronic myeloid leukemia followed at least 10 years after 
allogeneic bone marrow transplantation. Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology 20:2334-43, 2002 
 119. Guilhot F, Apperley J, Kim DW, et al: Dasatinib induces significant hematologic and 
cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid 
leukemia in accelerated phase. Blood 109:4143-50, 2007 
 120. Kantarjian HM, Giles F, Gattermann N, et al: Nilotinib (formerly AMN107), a highly 
selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia 
chromosome-positive chronic myelogenous leukemia in chronic phase following 
imatinib resistance and intolerance. Blood 110:3540-6, 2007 
 121. Cortes J, Kim DW, Raffoux E, et al: Efficacy and safety of dasatinib in imatinib-
resistant or -intolerant patients with chronic myeloid leukemia in blast phase. 
Leukemia : official journal of the Leukemia Society of America, Leukemia Research 
Fund, U.K 22:2176-83, 2008 
  20 
 122. le Coutre P, Ottmann OG, Giles F, et al: Nilotinib (formerly AMN107), a highly 
selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-
resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 
111:1834-9, 2008 
 123. Hochhaus A, Baccarani M, Deininger M, et al: Dasatinib induces durable cytogenetic 
responses in patients with chronic myelogenous leukemia in chronic phase with 
resistance or intolerance to imatinib. Leukemia : official journal of the Leukemia 
Society of America, Leukemia Research Fund, U.K 22:1200-6, 2008 
 124. Tokarski JS, Newitt JA, Chang CY, et al: The structure of Dasatinib (BMS-354825) 
bound to activated ABL kinase domain elucidates its inhibitory activity against 
imatinib-resistant ABL mutants. Cancer research 66:5790-7, 2006 
 125. O'Hare T, Walters DK, Stoffregen EP, et al: In vitro activity of Bcr-Abl inhibitors 
AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase 
domain mutants. Cancer research 65:4500-5, 2005 
 126. Branford S, Melo JV, Hughes TP: Selecting optimal second-line tyrosine kinase 
inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the 
BCR-ABL mutation status really matter? Blood 114:5426-35, 2009 
 127. Branford S, Rudzki Z, Walsh S, et al: Detection of BCR-ABL mutations in patients 
with CML treated with imatinib is virtually always accompanied by clinical resistance, 
and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor 
prognosis. Blood 102:276-83, 2003 
 128. Santos FP, Kantarjian H, Quintas-Cardama A, et al: Evolution of therapies for chronic 
myelogenous leukemia. Cancer journal 17:465-76, 2011 
 129. Goldman JM: Initial treatment for patients with CML. Hematology / the Education 
Program of the American Society of Hematology. American Society of Hematology. 
Education Program:453-60, 2009 
 130. Druker BJ, Guilhot F, O'Brien SG, et al: Five-year follow-up of patients receiving 
imatinib for chronic myeloid leukemia. The New England journal of medicine 
355:2408-17, 2006 
 131. de Lavallade H, Apperley JF, Khorashad JS, et al: Imatinib for newly diagnosed 
patients with chronic myeloid leukemia: incidence of sustained responses in an 
intention-to-treat analysis. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 26:3358-63, 2008 
 132. Bonifazi F, de Vivo A, Rosti G, et al: Chronic myeloid leukemia and interferon-alpha: 
a study of complete cytogenetic responders. Blood 98:3074-81, 2001 
 133. Quintas-Cardama A, Kantarjian H, Jones D, et al: Delayed achievement of cytogenetic 
and molecular response is associated with increased risk of progression among patients 
with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-
dose imatinib therapy. Blood 113:6315-21, 2009 
 134. Roy L, Guilhot J, Krahnke T, et al: Survival advantage from imatinib compared with 
the combination interferon-alpha plus cytarabine in chronic-phase chronic 
myelogenous leukemia: historical comparison between two phase 3 trials. Blood 
108:1478-84, 2006 
 135. Marin D, Milojkovic D, Olavarria E, et al: European LeukemiaNet criteria for failure 
or suboptimal response reliably identify patients with CML in early chronic phase 
treated with imatinib whose eventual outcome is poor. Blood 112:4437-44, 2008 
  21 
 136. Rosti G, Palandri F, Castagnetti F, et al: Nilotinib for the frontline treatment of Ph(+) 
chronic myeloid leukemia. Blood 114:4933-8, 2009 
 137. Kantarjian H, Shah NP, Hochhaus A, et al: Dasatinib versus imatinib in newly 
diagnosed chronic-phase chronic myeloid leukemia. The New England journal of 
medicine 362:2260-70, 2010 
 138. gruppen SK: Nationella Riktlinjer för diagnostik och behandling av Kronisk Myeloisk 
Leukemi, 2012 
 139. Socialstyrelsen: Dödsorsaksstatistik, 2011 
 140. Socialstyrelsen: Cancerstatistik, 2011 
 141. Kim YR, Cho HI, Yoon SS, et al: Interpretation of submicroscopic deletions of the 
BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation 
of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH. Genes, 
chromosomes & cancer 43:37-44, 2005 
 142. Buno I, Wyatt WA, Zinsmeister AR, et al: A special fluorescent in situ hybridization 
technique to study peripheral blood and assess the effectiveness of interferon therapy 
in chronic myeloid leukemia. Blood 92:2315-21, 1998 
 143. Sinclair PB, Green AR, Grace C, et al: Improved sensitivity of BCR-ABL detection: a 
triple-probe three-color fluorescence in situ hybridization system. Blood 90:1395-402, 
1997 
 144. Primo D, Tabernero MD, Rasillo A, et al: Patterns of BCR/ABL gene rearrangements 
by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: 
incidence and underlying genetic abnormalities. Leukemia : official journal of the 
Leukemia Society of America, Leukemia Research Fund, U.K 17:1124-9, 2003 
 145. Najfeld V: High performance of the BCR/ABL-extra sensitive (ES) probe for detection 
of der(9q) deletion in t(9;22) (q34;q11.2). Cancer genetics and cytogenetics 132:171, 
2002 
 146. Pelz AF, Kroning H, Franke A, et al: High reliability and sensitivity of the BCR/ABL1 
D-FISH test for the detection of BCR/ABL rearrangements. Annals of hematology 
81:147-53, 2002 
 147. Thorn I, Olsson-Stromberg U, Ohlsen C, et al: The impact of RNA stabilization on 
minimal residual disease assessment in chronic myeloid leukemia. Haematologica 
90:1471-6, 2005 
 148. Beillard E, Pallisgaard N, van der Velden VH, et al: Evaluation of candidate control 
genes for diagnosis and residual disease detection in leukemic patients using 'real-time' 
quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe 
against cancer program. Leukemia : official journal of the Leukemia Society of 
America, Leukemia Research Fund, U.K 17:2474-86, 2003 
 149. Gabert J, Beillard E, van der Velden VH, et al: Standardization and quality control 
studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of 
fusion gene transcripts for residual disease detection in leukemia - a Europe Against 
Cancer program. Leukemia : official journal of the Leukemia Society of America, 
Leukemia Research Fund, U.K 17:2318-57, 2003 
 150. Kaplan AP, Meier HL, Mandle R, Jr.: The Hageman factor dependent pathways of 
coagulation, fibrinolysis, and kinin-generation. Seminars in thrombosis and hemostasis 
3:1-26, 1976 
  22 
 151. Marin D, Ibrahim AR, Lucas C, et al: Assessment of BCR-ABL1 transcript levels at 3 
months is the only requirement for predicting outcome for patients with chronic 
myeloid leukemia treated with tyrosine kinase inhibitors. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 30:232-8, 2012 
 152. Hanfstein B, Muller MC, Hehlmann R, et al: Early molecular and cytogenetic response 
is predictive for long-term progression-free and overall survival in chronic myeloid 
leukemia (CML). Leukemia : official journal of the Leukemia Society of America, 
Leukemia Research Fund, U.K 26:2096-102, 2012 
 153. Simonsson B, Kloke O, Stahel RA: ESMO Minimum Clinical Recommendations for 
the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML). 
Annals of oncology : official journal of the European Society for Medical Oncology / 
ESMO 16 Suppl 1:i52-3, 2005 
 154. Hehlmann R, Ansari H, Hasford J, et al: Comparative analysis of the impact of risk 
profile and of drug therapy on survival in CML using Sokal's index and a new score. 
German chronic myeloid leukaemia (CML)-Study Group. British journal of 
haematology 97:76-85, 1997 
 155. Rinaldo-Matthis A, Haeggstrom JZ: Structures and mechanisms of enzymes in the 
leukotriene cascade. Biochimie 92:676-81, 2010 
 156. Peck MJ, Piper PJ, Williams TJ: The effect of leukotrienes C4 and D4 on the 
microvasculature of guinea-pig skin. Prostaglandins 21:315-21, 1981 
 157. Dahlen SE, Bjork J, Hedqvist P, et al: Leukotrienes promote plasma leakage and 
leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute 
inflammatory response. Proceedings of the National Academy of Sciences of the 
United States of America 78:3887-91, 1981 
 158. Marom Z, Shelhamer JH, Bach MK, et al: Slow-reacting substances, leukotrienes C4 
and D4, increase the release of mucus from human airways in vitro. The American 
review of respiratory disease 126:449-51, 1982 
 159. Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 
294:1871-5, 2001 
 160. Stenke L, Mansour M, Reizenstein P, et al: Stimulation of human myelopoiesis by 
leukotrienes B4 and C4: interactions with granulocyte-macrophage colony-stimulating 
factor. Blood 81:352-6, 1993 
 161. Stenke L, Samuelsson J, Palmblad J, et al: Elevated white blood cell synthesis of 
leukotriene C4 in chronic myelogenous leukaemia but not in polycythaemia vera. 
British journal of haematology 74:257-63, 1990 
 162. Tornhamre S, Stenke L, Granzelius A, et al: Inverse relationship between myeloid 
maturation and leukotriene C4 synthase expression in normal and leukemic 
myelopoiesis-consistent overexpression of the enzyme in myeloid cells from patients 
with chronic myeloid leukemia. Experimental hematology 31:122-30, 2003 
 163. Sjolinder M, Stenke L, Nasman-Glaser B, et al: Aberrant expression of active 
leukotriene C(4) synthase in CD16(+) neutrophils from patients with chronic myeloid 
leukemia. Blood 95:1456-64, 2000 
 164. Chen L: The Alox5 gene is a novel therapeutic target incancer stem cells of chronic 
myeloid leukemia. Cell Cykle 8:21:3488-3492, 2009 
 165. Haferlach T, Winkemann M, Nickenig C, et al: Which compartments are involved in 
Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the 
  23 
single cell level by combining May-Grunwald-Giemsa staining and fluorescence in 
situ hybridization techniques. British journal of haematology 97:99-106, 1997 
 166. Jacobsson B, Bernell P, Arvidsson I, et al: Classical morphology, esterase 
cytochemistry, and interphase cytogenetics of peripheral blood and bone marrow 
smears. The journal of histochemistry and cytochemistry : official journal of the 
Histochemistry Society 44:1303-9, 1996 
 167. Sala A, Voelkel N, Maclouf J, et al: Leukotriene E4 elimination and metabolism in 
normal human subjects. The Journal of biological chemistry 265:21771-8, 1990 
 168. Mattsson B, Wallgren A: Completeness of the Swedish Cancer Register. Non-notified 
cancer cases recorded on death certificates in 1978. Acta radiologica. Oncology 
23:305-13, 1984 
 169. Barlow L, Westergren K, Holmberg L, et al: The completeness of the Swedish Cancer 
Register: a sample survey for year 1998. Acta oncologica 48:27-33, 2009 
 170. Henson DE, Ries LA: The relative survival rate. Cancer 76:1687-8, 1995 
 171. Dickman PW, Adami HO: Interpreting trends in cancer patient survival. Journal of 
internal medicine 260:103-17, 2006 
 172. Ederer F HH: Instructions to IBM 650 programmers in processing survival 
computations: Methodological note No 10 Bethesda, MD National Cancer Institute. 
1959 
 173. Dickman PW, Sloggett A, Hills M, et al: Regression models for relative survival. 
Statistics in medicine 23:51-64, 2004 
 174. LFN: General Guidelines for Economic Evaluation from the Pharmaceutical Benefits 
Board, 2003 
 
 
 
